ABSTRACT Lipid excipients are applied for numerous purposes such as taste masking, controlled release, improvement of swallowability and moisture protection. Several melting techniques have evolved in the last decades. Common examples are melt coating, melt granulation and melt extrusion. The required equipment ranges from ordinary glass beakers for lab scale up to large machines such as fluid bed coaters, spray dryers or extruders. This allows for upscaling to pilot or production scale. Solvent free melt processing provides a cost-effective, time-saving and eco-friendly method for the food and pharmaceutical industries. This review intends to give a critical overview of the published literature on experiences, formulations and challenges and to show possibilities for future developments in this promising field. Moreover, it should serve as a guide for selecting the best excipients and manufacturing techniques for the development of a product with specific properties using solvent free melt processing.

KEY WORDS agglomeration · coating · extrusion · lipid · melt · solvent-free

ABBREVIATIONS

API  Active pharmaceutical ingredient
BET  Brunauer–Emmett–Teller theory
Caco Colon adenocarcinoma cells
DSC  Differential scanning calorimetry
DVS  Dynamic vapor sorption
EDX  Energy dispersive x-ray microanalysis

FDA  Food and drug administration
FT-IR Fourier transform infrared spectroscopy
GRAS Generally recognized as safe
HLB  Hydrophilic lipophilic balance
HSM  Hot stage polarization microscopy
IIG  Inactive ingredient guide
INF  Interferon
NIR  Near infrared spectroscopy
PAT  Process analytical technology
PEG  Polyethylene glycol
PgP  P-glycoprotein
SEM  Scanning electron microscope
TGA  Thermogravimetric analysis
XPS  X-ray photoelectron spectroscopy
XRD  X-ray diffraction

INTRODUCTION

The importance of lipid-based solid oral formulations has increased during the last decades, due to their outstanding benefits such as providing modified release profiles or taste masking using solvent-free processing techniques. Lipid-based excipients were first used in the 1960s for embedding drugs in a wax matrix in order to sustain drug release (1,2). In the more recent years these excipients were successfully used in oral drug delivery systems to enhance the bioavailability of poorly aqueous soluble drugs (3–5). Furthermore, taste masking and the improvement of swallowability have been achieved with these excipients (6). Further reasons for the application of lipids in a formulation may be (I) shelf life extension by protecting the drug from other ingredients or from environmental influences (II) the reduction of gastric irritation (III) the improvement of general attributes like flowability, lubrication performance, compressibility or mechanical resistance (7,8). Common techniques to obtain solid lipid-based
formulations are: spray congealing/drying, adsorption on solid carriers, melt granulation/melt extrusion, supercritical fluid based methods, or processing of solid lipid nanoparticles (9). The major difference between these methods is whether or not solvents are applied during the process. Several formulations described in the literature are prepared by spray techniques involving lipid excipients emulsified in water or dissolved in organic solvents and also aqueous dispersions of solid lipid nanoparticles (9–12). However, there are several drawbacks associated with the presence of solvents. An aqueous medium requires a time-consuming solvent evaporation step and residual moisture may affect product stability due to drug hydrolysis. Organic solvents offer a considerably faster evaporation step, though these solvents are much more expensive, flammable and often toxic. This causes other issues like the prevention of hazards to employees and environment, and additional costly steps for solvent recovery and disposal (13).

On the contrary, working with molten excipients provides the outstanding benefit of evading any solvent. Thereby, all the described disadvantages can be overcome. Despite the promising benefits, there are also some problems involved with the application of solvent-free melting techniques with lipid based excipients, e.g., heat sensitive drugs may undergo degradation and polymorphic and morphological changes of the lipid or crystallinity changes of the drug may alter the product performance over time.

Countless studies on the development of solid oral formulations using solvent-free melting techniques have been published in the last decades. The current work is a critical review of these studies based on the applied excipients, processing strategies and the analytical methods for the characterization of the excipients and the end product. The focus is on manufacturing processes, which are categorized into three main strategies, i.e., melt extrusion, melt coating and melt agglomeration. Additionally, this review intends to give support for selecting appropriate lipid excipients and suitable solvent-free manufacturing techniques to obtain the desired end product.

**LIPID-BASED EXCIPIENTS**

Substances containing a fatty acid in their chemical structure are referred to as lipid-based excipients. Even though fatty acids occur naturally and are part of the daily diet, a general statement about the safety and toxicity of their derivatives cannot be made. A reasonable approach is the selection of lipid-based excipients listed as “generally recognized as safe” (GRAS) or registered as inactive ingredient in the “inactive ingredient guide (IIG)” published by the United States Food and Drug Administration (FDA) or the use of food excipients, which only require a simplified authorization procedure for pharmaceutical application (14–16). However, physiological and biopharmaceutical interactions with other formulation compounds as well as additional toxicological effects of the formulation are not taken into account (14,17). Many lipophilic compounds act as substrates for the P-glycoprotein (Pgp), a membrane-bound ATP-dependent efflux pump in the enterocyte that transports xenobiots back into the intestinal lumen, and for the intestinal cytochrome P450 enzyme, a hydroxylase that metabolizes xenobiots to more water soluble, often inactive derivatives that can be excreted through the urinary bladder (18,19). Their inhibition increases the absorption of drugs out of the intestinal lumen and reduces the metabolism into inactive drug derivatives leading to an overall higher drug exposure, which may go along with more pronounced side effects (18). An in vitro study, for instance, revealed that lipid-based additives such as Peceol and Gelucire 44/14, both approved as GRAS, inhibit the PgP-mediated efflux in human colon adenocarcinoma cells (Caco-2) by decreasing the PgP-protein expression (20). However, the prediction of the real in vivo impact is hardly possible, as it strongly depends on the applied excipient concentration, the binding-affinity, the therapeutic index of the drug, and even on the individual genetic protein polymorphism (18,21).

Nevertheless, the number of possible combinations of the molecular structure is virtually infinite, depending on the fatty acid (e.g., chain length, the grade of saturation, the presence of branches, the kind of chemical bond (e.g., ether/ester) and nature and number of the linked molecule (e.g., glycerol, additional fatty acids, propylene glycol, polyglycerol, sucrose etc.). This leads to a wide field of application possibilities of these excipients comprising solubility enhancement as well as controlled drug release. A useful indicator to estimate the drug release is the hydrophilic-lipophilic balance (HLB) a numerical rating scheme based on the water solubility and polarity of the excipient (22,23). As the contact angle and, consequently, the wetting behavior are affected by the HLB, excipients with a lower HLB ≤5 can be expected to retard the original drug dissolution pattern (24). Apart from polarity the gel-formation properties, melting point, crystallinity and porosity as well as the nature of the drug (e.g., solubility, melting point) itself and the way the drug is integrated into the formulation (e.g., core/shell, matrix), can play an integral role in in vitro drug release (24–26). Table I gives an overview of the substance classes and associated materials applied as excipients in published formulations for both pharmaceutical and food supplementary products. The most frequently, purely used excipients in the recent past are Compritol 888 ATO for controlled release, Precirol ATO 5 (depending on coating amount and drug (27,28)) for taste masking, Gelucire 50/13 for solubility enhancement of poor soluble drugs, and stearic acid for pH-dependent release (e.g., enteric coating). In particular, Precirol ATO 5 and Gelucire 50/13 are prone to exhibit polymorphic changes and have therefore been associated with storage instabilities. Chapter 3.3 lists a few strategies to circumvent this issue.
Lipid-based Solid Oral Formulations

Characterization Methods, Challenges and Controlling Strategies

Lipid-based excipients often involve acylglycerols in their structure or their blend. Acylglycerols exist in up to four different crystalline structures: the pseudo-hexagonal sub-α, the hexagonal α-, the orthorhombic β′- and the triclinic β-form (in order of increasing thermodynamic stability) (174–177). These forms not only differ in their packing density and stability, but also in their physico-chemical properties such as their melting point, recrystallization rate, and solubility in water (177–179). For instance, the transformation from the thermodynamically instable and less dense α-form to the most stable and densely packed β-form should result in the reduction of wettability. Another effect associated with polymorphic transformation occurs during the transformation from the hexagonal α- to the triclinic β-form while passing the orthorhombic β′-form. The altered geometric integrity of the crystalline structure leads to the spontaneous formation of flake-like fractal structures on the surface also known as “blooming” (164). Interestingly, the impact of this alteration on drug release described in the literature points towards two different directions, both causing a change in drug release after storage and indicating formulation instability. On the one hand, the rough surface was described as super water-repellent with contact angles larger than 150°, meaning a significant reduction of wettability (180,181). Several studies have proven the formation of fractal structures on the surface of different lipid formulations with SEM images, which seems to be associated with an undesired retarded drug release after storage. It is of particular interest, that all described formulation comprised mono-, di- or triacylglycerides in a extruded mixture with the drug (159,182). This effect was even able to overrule the dissolution enhancing effect of some surfactants (e.g., glyceryl monostearate, HLB 3.8) (131). On the other hand, several formulations have been reported showing a significant increase in their dissolution rate after storage (80,102,183).

Interestingly, these formulations all included a compound with a high HLB and a lower melting point (e.g., Caprol PGE 860), which might form an amorphous partition in the surrounding of the crystallized lipid structures. The storage above the melting point increases the mobility of this amorphous phase and induces phase separation and may result in an increased wettability. This effect can be promoted additionally by changes in the structure of the crystalline phase due to

---

**Table I** Overview of Lipid Based Excipients and Their Application in Literature

| Substance class | Materials and application examples in literature |
|-----------------|--------------------------------------------------|
| Waxes           | Bees wax (29–34), carnauba wax (29,31,32,35–41)   |
| Fully or partially hydrogenated vegetable oils and fats | Hydrogenated coco-glycerides (e.g., Witocon 42/44, Witepsol E 85) (42–45), hydrogenated palm fat and oil (e.g., Softisan 154) (46,47), hydrogenated castor oil (e.g., Cutina HR) (48–58), hydrogenated rape oil (59), hydrogenated cottonseed oil (e.g., Sterotex, Lubritab) (60–62), hydrogenated soybean oil (e.g., Sterotex HM) (63–67), hardened soybean oil (e.g., Dynasan 120) (68) |
| Polyoxyglycerides | Gelucire 55/18 (69,70), Gelucire 50/13 (71–85), Gelucire 44/14 (75,86–101), Gelucire 39/01 (102–104), Gelucire 43/01 (104–107), Gelucire 50/02 (28,69,88) and Gelucire 64/02 (108), Compritol HD 5 (109) |
| Fatty acids      | Myristic acid (59), palmitic acid (110–113), stearic acid (35,36,57–59,111,113–119), behenic acid (59,120), Syncrowax AVI-C, Emulsifying wax NF (37) |
| Monoacylglycerides | Glyceryl monostearate (e.g., Inmwtor 491, Atmul 84 K) (39,55,57,114,115,121–132), glyceryl monoleate (133,134), glycerol monolaurate (84) |
| Diacylglycerides | Glyceryl palmistearate (Precirol ATO 5) (27,43,135–142) and glyceryl dibehenate (Compritol 888 ATO) (29,137,44,54,139,142–158) with 40–60% of diacylglycerides |
| Triacylglycerides | Trilaurin (Dynasan 112) (159,160), trimyristin (Dynasan 114) (44,141,142), tripalmitin (Dynasan 116) (159–162), tristearin (Dynasan 118) (45,131,159,163–165), tribehenin (e.g., Syncravax HR-C), triglyceride of long fatty acids (Syncravax HGL-C) (37,147) |
| Animal fats      | Cow ghee (41,166,167) |
| Polyglycerides   | Tetraglycerol pentostearate, tetraglycerol monostearate (168), polyglycerol-6-stearate (47) |
| PEG fatty acid esters | PEG-6-stearate (e.g., superpolystate) (169) |
| Sucrose fatty acid esters | Sucrose laurate (170,171), sucrose stearate (61,172), sucrose palmitate and sucrose behenate (173) |
polymorphic transition during storage ("thermally induced phase separation-recrystallization"). These phenomena are highly dependent on the characteristics of the raw material (e.g., melting point, miscibility, crystal structure) as well as on the temperature and mobility of the molecules. In particular Gelucire 50/13, which is a mixture of mono-, di- and triacylglycerides (C_{12}-C_{18}) and polyethylene glycol esters, is already known to show an increased release rate due to thermally induced phase separation and polymorphic transformation (184). The last example, Precriol ATO5, will emphasize, how complex and severe the impact of the polymorphic behavior on formulation stability can be. Hamdani et al. reported a complete loss of the prolonged release properties after storage at accelerated conditions of melt-granulated pellets comprising Phenylophrine, Lactose 450, Precriol ATO 5 and different amounts of unmelted Compritol 888 ATO. However, the storage at 25°C/60% r.h. decreased the dissolution rate significantly (138). Reitz et al. reported a similar impact on drug dissolution rate by using Precriol ATO 5 for manufacturing theophylline extrudates. Although the dissolution rate decreased in the first week, after 9 months it was significantly higher than directly after manufacturing (142). The mechanism behind these observations is not explained, but it is nonetheless possible that the formation of more stable polymorphs and fractal structures reduces the dissolution rate after storing at room temperature. The increase of dissolution rate observed after storage at higher temperatures lacks an explanation and has to be associated with the heterogeneous composition and sensibility to thermal treatment (141). Nevertheless, the formulation design (e.g., melting technique, excipient composition, drug properties and interaction with excipients etc.) may also affect the drug release during storage.

As the dissolution profile is influenced by various effects and complex interactions, it is not surprising that there also exist stable formulations with excipients that caused storage instabilities in other studies (139,185). Hence, it is crucial to understand the physicochemical behavior of the raw materials and the interaction and impact on the properties of the processed formulation. Therefore, the following subchapters will focus on the characterization methods for the excipients and the product after thermal processing. Subchapter 3.3 intends to show how storage instabilities may occur and how they can already be prevented in the preformulation stage.

### Characterization of the Excipients

Changes in polymorphism and morphological structure as well as phase separation phenomena are probably the most common effects inducing formulation instabilities during storage. Therefore it is crucial to develop a deep understanding of the physicochemical properties of the selected excipients before and after melting, under different conditions (e.g., time, temperature), and in mixtures with each other and with and without the drug. This step saves time and costs in the process development phase. Table II summarizes methods used to gain insight into physico-chemical properties.

### Characterization of the Product After Melt Processing

Apart from the well-established powder and surface-morphology characterization techniques (72,109,110,126,187,188), analytical in vitro tools are also available for the estimation of the subsequent in vivo dissolution behavior of the formulation in the body. Common in vitro methods for this purpose are dissolution tests with biorelevant media and lipolysis studies with pancreatin (182,189–193). Biorelevant media contains physiologically relevant surfactants including a mixture of bile salts (e.g., sodium taurocholate), phospholipids, pancreatic lipase to simulate lipolysis, and buffer and salts are added to adjust the pH and the osmolarity of the medium to imitate physiological conditions (182). Witzelb et al. showed that the release from lipid-based matrices in biorelevant media highly depends on the structure of the lipid. Cetyl palmitate and glyceryl monostearate, for instance, exhibited a significantly faster release in biorelevant media than in HCl due to a different solubilization with surfactants and enzymatic degradation in case of glyceryl monostearate. Other lipid matrices such as glyceryl tripalmitate and glyceryl dibehenate indicated only a minor effect of the changed medium on drug release (182). In addition, lipolysis measurements revealed that lipid digestion of the pancreatic lipase does not only depend on the chain length, but also on the grade of esterification, on the solid state, and the ability for solubilization (182,194,195). Hence, it cannot be excluded that changes in crystallinity and solubility due to polymorphic transition may have a significant impact on in vitro and in vivo drug release profiles (182). Along with an optimal dissolution rate, taste masking is often an important objective in formulation development (33,43,196,197). This is usually evaluated in sensory studies with trained volunteers (33,198–200). Some studies also involve cats, which are sensitive to bitterness and scorn bitter food with insufficient taste masking (197). A simple in vitro method is the use of a disintegration tester (1 min stirring, pH 7.4) for the evaluation of the short time release amount in a pH close to that in the mouth (196), but also the results of a test of the first minutes of dissolution have been utilized (201). Another method reported is the mini column method, which represents a release test that attempts to simulate the anatomy and physiology of the oral cavity (201,202). A more sophisticated method is the measurement of dissolved samples with an electronic tongue, which consists of different potentiometric sensors and a pattern recognition system (203,204) (Table III).
Strategies for Controlling Polymorphism and Formulation Stability

Several approaches to control lipid polymorphism are conceivable, whereby only some have been applied in the existing literature:

- **Tempering during processing:**
  
  Process temperatures are kept between the melting point of the instable α- and stable β-form, in the area where the direct recrystallization of the stable β-form predominates over the β′-form (205). This prevents the formation of fractal structures (159) and the alteration of the dissolution profile due to morphological changes during storage. The recrystallization of the thermodynamically stable β-form is significantly slower than of the α-form. This may result in processing difficulties such as agglomeration in a fluid bed melt coating process or incomplete resolidification after spray chilling in a spray dryer. Melt extrusion is an appropriate technique to generate storage stable extrudates with this technique (142).

- **Tempering after processing ("maturing"):**
  
  In the first step recrystallization of the instable α-form is enabled by ensuring optimum process conditions. Maturing is performed after the process at elevated temperatures below but close to the melting point of the instable α-form. The maturing step is time consuming and may require additional equipment (e.g., a drying chamber). Alternatively, a fluid bed coater can be used for that step, as this prevents the formation of agglomerates. The α → β transformation causes the formation of fractal structures and the alteration of the dissolution profile before and after maturing (64,66,146). A complete transformation is essential for achieving a storage stable formulation.

- **Addition of crystallization seeds ("template effect"):**
  
  The stable β-form or material with a comparable saturation grade and a chain length difference of n ≤ 4 can be used as seed material (177). The seed material is added to the molten lipid in the solid state. The presence of seeds acting as templates should accelerate the direct recrystallization of the molten material into the stable β-form (67,77). In case the stable β-form recrystallizes directly from the melt during the process, fractal structures should be avoided (159,164). When seed material is applied in form of a spraying suspension, the amount is limited to prevent nozzle clogging. The efficiency of this measure in accelerating the recrystallization and its effect on the purity of the stable phase haven’t been analyzed in detail yet.

- **Avoidance of melting:**
  
  The polymorphic transformation of most lipid excipients is monotropic. That means that if melting of the raw material, which is usually provided by the supplier in the stable β-form, can be avoided, the storage instabilities due to polymorphic changes can be eliminated. The challenge herein lies in the processability. Solid lipid excipients with a critical polymorphic behavior should either have a...
The addition of polymorphic modifiers: dissolution, taste) (in vivo /142 /179 Becker, Salar-Behzadi and Zimmer → 206 /32 data is /33 zero order) or immediate lipolysis with pancreatin, claimed that solid bitterness) Sensory studies with trained or untrained volunteer collective, electronic β nucleation rate, crystal floating behavior methods for product after melt formation of a physical mixture between drug and lipid case of aiming at a controlled release formulation, the immediately after resolidification (morphism or transforms into the stable form during or that has an appropriate viscosity and/or shows no poly- viscosity or have to be combined with an excipient suitable viscosity or have to be combined with an excipient that has an appropriate viscosity and/or shows no polymorphism or transforms into the stable form during or immediately after resolidification (161,207–209). In the case of aiming at a controlled release formulation, the formation of a physical mixture between drug and lipid excipient might be the wrong path as the dissolution rate of the physical mixtures may be higher than that of the solidified melt-dispersion (140,210).

- Addition of polymorphic modifiers:
  
  Several emulsifiers are known to have a significant impact on the crystallization (e.g., nucleation rate, crystal growth and morphology) and polymorphic transition of lipid excipients (211,212). Although numerous publications exist on this topic, the majority of these studies discuss applying commercially available additives, which often consist of a chemical mixture with high heterogeneity and differ in their composition between different suppliers and even batches (211). Additional effects such as their concentration, kind of lipid, degree of undercooling as well as the use of agitation may have a significant influence on the crystallization and polymorphic process (211). Most of the application examples derive from and are addressed to the food industry and only a few studies are specific to the pharmaceutical industry (131,162,213,214). There are several examples how modifiers can impact the polymorphism: Sucrose esters obstruct the α → β and β′ → β transition in tristearin and hydrogenate sunflower oil due to their high rigidity and some representatives (e.g., P-170, S-170) also affect the crystal size of the high-melting fraction of milk fat (215–217). Garti et al. claimed that solid emulsifiers such as Span 40 (sorbitan monopalmitate), Span 60 (sorbitan monostearate), Span 65 (sorbitan tristearate) as well as glyceryl monostearate were able to stabilize the α-form and prevented the transformation into the stable β-form in tristearin (218,219). However, ageing

### Table III Characterization methods for product after melt processing

| Parameter                                           | Methods                                                                 |
|-----------------------------------------------------|-------------------------------------------------------------------------|
| Size distribution, sphericity, shape                | Sieve analysis, digital imaging, laser diffraction (76,188,198)         |
| Fractibility                                        | Fribrator (33,48)                                                       |
| Flowability, compactibility, compressibility        | FT4 powder rheometer, flow time (funnel), angle of repose, graduated   |
|                                                     | cylinder (tapped/ bulk density, hausner ratio, carr index), texture     |
|                                                     | analyzer (tensile strength profile) (48,169,198)                        |
| Hardness                                            | Hardness tester, texture analyzer (32, 48,68)                          |
| Porosity                                            | Mercury porosimeter (142,188,302)                                      |
| True density, specific surface area (BET)           | Helium pycnometer (81,158,188)                                         |
| Surface topography and morphology                  | Scanning electron microscopy (SEM) (179,188)                           |
| Microstructure                                      | (Cryogenic) Transmission electron microscopy (TEM) (206)              |
|                                                     | Synchrotron radiation computed microtomography (SRµ-CT) (157)          |
| Surface structure                                   | Atomic force microscopy (AFM), stereomicroscopy (179)                 |
| Coating thickness                                   | Optical coherence tomography (OCT)                                     |
|                                                     | Terahertz spectroscopy (265,267)                                       |
| Surface polymorphism                                | Attenuated total reflection fourier transform infrared spectroscopy (ATR-FTIR) (44) |
| Elemental composition & homogeneity                 | Energy dispersive x-ray microanalysis EDX (84,306)                     |
| Chemical distribution & homogeneity                 | Raman confocal microscopy (raman mapping) (126)                        |
| Atomic composition & homogeneity                    | X-ray photoelectron spectroscopy (XPS) (188,366)                       |
| Buoyancy lag time                                   | Floatability (visualization/counting method) (83,106,133,148,149)      |
| Non-invasive, in vivo floating behavior             | γ- scintigraphy with radiolabeled technetium (99m Tc), radiographic    |
|                                                     | incorporation studies (107)                                            |
| Taste (e.g., bitterness)                            | Sensory studies with trained or untrained volunteer collective, electronic |
|                                                     | tongue, short-time dissolution profiles by using disintegration        |
|                                                     | tester (33,196,199,200,203,238)                                       |
| Dissolution                                         | Dissolution tester I/II, data fitting to mathematical kinetic models for |
|                                                     | controlled release (e.g., zero order) or immediate release (30,57,106,188) |
| In vitro prediction of lipid digestion in vivo      | Dissolution with biorelevant medium; in vitro lipolysis with pancreatin, |
|                                                     | construction of IVIVC-model in case in vivo data is available (9,182,189,190,191) |
| Storage stability at accelerated or intermediate conditions | Evaluation of quality attributes (e.g., dissolution, taste) (43,91,138,139) |
Selection of polymorphic excipients: Crystal size, blooming, phase separation and hexagonal triglycerol-l-stearate, sorbitan mainly used DSC and powder X-ray diffraction Dynasan 114) (cooling rate, ad- etc., fluid bed coating). Specification of storage temperature: Transformation due to an increase in Precirol Precirol ATO 5, Compritol 888 ATO, Gelucire 50/80 and polysorbates (Tween 60, 65, 80) and sorbitan monolaurate (Span 20) were proven to promote the α → β transformation due to an increase in molecular mobility (218,220). In the pharmaceutical industry this approach was used to coat N-acetylcysteine in a fluid bed coater with a coating consisting of tripalmitin and polysorbate 65 (162). As an advantage, the process temperatures can be kept to a minimum, which is preferable for drugs sensitive to heat, and the transformation and morphological changes will be complete before storage. However, it must be borne in mind that phenomena apart from polymorphism can lead to storage instabilities in particular if a liquid or semi-solid emulsifier is used in a greater amount (e.g., phase separation). Furthermore, the application of a higher amount of low-melting excipients can pose a problem if melt coating (e.g., fluid bed coating) or fast recrystallization in general is required. Thus, it is wise to take the time and effort for pre-formulation studies exploring the polymorphic and morphological behavior (e.g., crystal size, blooming, phase separation etc.) at different conditions (e.g., temperature, cooling and recrystallization rates, concentration etc.).

- Selection of excipients without/with stable polymorphism

Waxes such as carnauba wax, bees wax and stearyl stearate are stated to be non-polymorphic materials (40,46,221), which avoid storage instabilities associated with polymorphic changes. In particular the high melting point and brittleness of carnauba wax can induce processing problems such as nozzle clogging. Carnauba wax and bees wax have been most frequently used for controlled release formulations, but also immediate release is feasible with the addition of dissolution enhancers. Polyglycerides are said to be non-polymorphic, but stable in the α-crystalline form (222,223). The amount of glycerol- and esterified fatty acid molecules contributes to the HLB and can be adjusted in a wide polarity range and oligoglycerols with a degree of polymerization of up to 10 are approved by the FDA (224). Polyglycerol bears more functional groups for modification than PEG, and therefore shows a higher adaptability to different requirements such as the melting point or viscosity. However, these materials have been overlooked by the pharmaceutical industry for a long time (224).

- Selection of polymorphic excipients:

Lipid excipients consisting of a complex mixture of glycerol molecules with different degrees of esterification (e.g., Precirol ATO 5, Compritol 888 ATO, Gelucire 50/13 etc.) and/or of esters of different fatty acids (e.g., Precirol ATO 5) should be treated with particular caution (70,225). The high heterogeneity leads to a complex polymorphic behavior difficult to predict during melt processing and storage (137). The polymorphic behavior of Compritol 888 ATO, which mainly consists of glyceryl dibehenate, has been studied extensively with DSC, time-resolved synchrotron x-ray diffraction and infrared spectroscopy at different conditions (e.g., cooling rate, addition of pure acyl glycerides etc.) (135,226). These studies revealed that the ratio of mono-, di- and triheinen and especially the monobehenin amount is important for the formation of a pseudohexagonal sub-α and hexagonal α-phase (226). In particular the less stable and compact sub-α-form shows a higher drug incorporation, which is desired in the preparation of solid lipid microparticles (226,227). Therefore a variation in the batch composition of the supplier as well as the mixture with excipients containing monoacylglycerides themselves can lead to changes in the equilibrium and different polymorphic behavior (226). Nevertheless, Compritol 888 ATO has been widely used in controlled release formulations and seems to be able to provide a stable release profile during storage (43,228). In contrast, the literature seems to lack polymorphic studies for Precirol ATO 5 with a similar degree of detail. Hamdani et al. mainly used DSC and powder X-ray diffraction to investigate the sensitivity of the polymorphism on thermal treatment of Precirol ATO 5 (137). The complex polymorphic behavior due to the high homogeneity of the mixture led to several studies that showed an altered dissolution profile (138,142). However, the higher complexity of the aforementioned materials also brings advantages such as the broader melting and recrystallization range, which leads to a better spreading and higher robustness against process changes compared to pure materials with a sharp recrystallization profile such as triacylglycerides (e.g., Dynasan 114) (142).

- Specification of storage temperature:

Transformation kinetics and phase separation phenomenen are both temperature dependent (26,82). The selection and specification of adequate storage conditions might be the last way to prevent or at least slow them down to a minimum. However, this approach is less favored by the pharmaceutical industry as patient compliance is an issue.
SELECTION OF LIPID-EXCIPIENTS AND MELT PROCESSING TECHNIQUES

Several techniques have been described in the literature on solvent-free preparation of lipid-based solid, oral formulations. Nevertheless, the first step in formulation development should always be a careful selection of the lipid excipients (and other excipients if necessary). A useful, rationale based approach is provided by the FDA in the ICH guideline Q8 within the framework of the concept of quality by design (QbD) (229). According to this guideline a quality target product profile (QTPP) should be defined for the final or intermediate product. This QTPP should include all desired characteristics such as the dosage form, drug load, particle size, bio-availability, dissolution behavior, taste and stability (230). Based on the QTPP the next step will be the definition of the critical quality attributes (CQA) for the excipients and the drug and their appropriate specification limits, which must be met to ensure the desired product quality and patient safety (229). Typical CQAs are, for instance, the dissolution rate, the particle size distribution, the maximum permissible impurity profile (231) as well as the stability of the formulation (232). Rosiaux et al. (26) gave an overview of formulation parameters (e.g., HLB, excipient characteristics, further additives) that can be used to adjust the drug release from lipid matrices. Pore formers or surfactants with higher polarity accelerate the drug release, whereas increasing the concentration and melting point of the hydrophobic lipid excipient can be used to slow down the drug release (26). Taste masking with an immediate release profile can be achieved by applying lipids with a comparably low melting point such as Dynasan 114, Dynasan 116, Precirol ATO 5 or Witocan 42/44 (16,42,162,233–235). However, excipients with a melting point near room temperature may result in an inferior product quality due to poor flowability, a tendency to form great agglomerates and the risk of morphology changes during storage (236). Hence, comprising a liquid or a very low melting (<40°C) excipient in the formulation has to be well considered and the amount kept as low as possible. The ideal compromise between sufficient taste masking and immediate release may be found by applying a statistical design (DOE) to achieve an optimal adjustment of the critical process input parameters (CPP). Further consideration should be given to physical or chemical interactions between the chosen lipid excipients and the drug with special regard to temperature induced degradation and changes in crystallinity (solid solution, polymorphic changes). The selection of equipment and processing technique depends on the desired dosage form and particle size distribution as well as on already existing equipment and characteristics of the active ingredient and chosen excipients. The most common equipment in the industry used for melt processing are the extruder, the high shear mixer, the fluid bed, the pan coater and the spray dryer, which all allow for upscaling. Depending on the desired solid dosage form, a great number of different downstream processes are addressed in the literature, such as spheronization (49,69,109,209), molding (74,95,133,183,237,238), capsule filling (87,88,91,98,100,102,139,239–246), injection moulding (247,248), freeze pelletization (121,249), pastilation (250), milling (122,196) or tableting (92,156,251). Nevertheless, it should be obvious, that manufacturing costs will rise with the addition of further process steps and, therefore, should be considered thoroughly in advance. Table IV summarizes the common advantages and disadvantages associated with the melt processing technique in the respective equipment. A comparison with the required QTPP may provide the first support for the selection of the appropriate technique and equipment.

The following chapter will focus on the developed formulations and associated characteristics of the final product, on the basis of the categories melt extrusion, melt coating and melt agglomeration. At this point it is worthy of note that the terms for the melting techniques are not used consistently in the literature, especially when the topics melt coating and melt granulation are concerned (31). The fundamental differences between these techniques lie in the distribution of the API and the size of its contact surface with the lipid excipient. Melt extrusion provides a homogeneous solid dispersion after processing, while the distribution is less homogenous and the contact surface of the API and the lipid is smaller when melt agglomeration by high shear mixing and in particular melt coating are used. Nevertheless, the delimitation between these terms is complicated. For instance, several downstream processes of melt extrusion allow for the formation of pellets and granules, and with melt coating techniques a drug / lipid dispersion may be sprayed on nonpareils creating a solid dispersion layering.

Melt Extrusion

The classic equipment for the melt extrusion process is the extruder, which consists of a single- or twin-screw system. In both systems the screw is positioned in the center of a heatable stationary barrel. Three zones within the extruder are named after their individual function.

1. Feed zone: maximum pitch between barrel and screw flight

   The feed material enters this zone through a gravimetric or volumetric hopper, is mixed under low pressure and transported by the screw rotation to the compression zone.

2. Compression zone: continuous reduction of the pitch along the screw

   The steady pressure increase leads to compression, particle size reduction and more effective shearing and
Table IV: Overview Advantages and Disadvantages of Equipment Appropriate for Melting Processes

| Equipment         | Processing                  | Advantages                                                                                                           | Disadvantages                                                                                           |
|-------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Fluid bed         | Melt coating                | • High drug load (252)  
• Wide range of particle sizes processable (35 µm–5 mm) (253,254)  
• Efficient cooling step in the same equipment  
• PAT-tools: Raman, NIR, particle size (255–258)  
• sC:  
  ○ Adaptable for (slightly) heat sensitive drugs (short exposure to melt) (162,259)  
  ○ relative narrow PSD (narrowing in process) (126,260)  
  ○ sufficient taste masking with less coating prerequisite: spherical shaped, narrow PSD of core (33)  
• sC versus iC:  
  ○ higher coating amount applicable  
  ○ lower risk of agglomeration  
• sMA versus sMA:  
  ○ significant faster process (industry) (126, 261).  
• sMA versus iMA:  
  ○ more adjustable parameters to control process/product quality | • Discontinuous batch processing, minimum size dependent on machine and core density (~2.5–200 g), problem: expensive drugs  
• esp. sC:  
  ○ Multiplicity of parameters: high level of know-how required (62,252)  
  ○ Several requirements for core:  
    ○ low friability (avoids abrasion), low cohesiveness, good flowability, PSD as small as economically possible (avoids diverse coating thickness) (254,260), regularly shaped (no needles (253)), smooth surface, bulk powder density (0.5–1.0 g/mL (253), certain heat stability – costly or availability limited – additional costs for granulation – necessary for batch reproducibility (262)  
• sC and sMA:  
  ○ limited amount of insoluble compounds in the coating (avoids nozzle clogging) (126)  
  ○ several requirements for the exipients: e.g., viscosity (~<300 mPas/80°C), melting point (~40–85°C) to prevent instabilities and nozzle clogging, narrow resolidification range (avoids agglomeration), homogenous miscibility (253). – only few suitable excipients |}

| Pan coater        | Melt coating                | • Cheaper alternative for sC in fluid bed (41,263,264)  
• PAT-tools (OCT, Raman, NIR) (265–267)  
• sC versus pC:  
  ○ uniform film formation and high coating efficiency, better process control (264) | • Only suitable for larger particle sizes (600–5000 µm) (268)  
• pC:  
  ○ Feasibility of upscaling questionable  
• sC:  
  ○ Almost the same requirements as for sC in fluid bed  
• esp. mMA:  
  ○ Inappropriate for thermosensitive drugs  
• Chemical reactions are accelerated  
• mMA:  
  ○ Time-consuming cooling step necessary (further cooling equipment might be required)  
• esp. mMA:  
  ○ Denser product compared to fluidized bed, reduced compressibility and dissolution rate (275–278) |}

| High shear mixer  | Melt agglomeration          | • Multifunctional mixing device, may avoid investment for specialized equipment  
• PAT-tools (Raman, NIR) (269,270)  
• HF: mMA:  
  ○ Convective mixing mechanism: applicability to a wide variety of drug formulations (e.g., fine, cohesive material, broader PSD, binders with higher viscosity etc.) (271,272)  
• mMA:  
  ○ Simple, less process: parameters (273,274))  
• sMA versus sMA:  
  ○ More adjustable parameters for finer process control | |}

| Extruder          | Melt extrusion              | • Adaptable for heat sensitive drugs: application of low recrystallizing excipients (43), reduction of residence time, or addition of antioxidants (279)  
• High content uniformity (280) | • High level of know how required, high modularity of process  
• Formulation development time- and material-consuming (282)  
• Additional expensive downstream equipment required  
• Storage stability might be an issue (e.g., recrystallization of amorphous drug) (284) |}
mixing. The heated barrel wall and the frictional heat are used to melt or at least soften the material. Additional equipment such as conveying and kneading elements may be used for the mixing, homogenization, venting and kneading process.

3. Metering zone: constant minimum pitch

The continuous high pressure supports a homogenous and steady material flow to and through the die.

After melt extrusion the product is cooled and shaped downstream in further processing units, such as hot strand cutters, calendaring, chill rolls, or spheronizers/marumerizers (128, 280, 281, 290–294).

Melt Extrusion is widely used for two main purposes, namely enhancing the bioavailability of poorly soluble drugs and the development of formulations with modified release profiles (294–296). Jannin et al. (9) and Keen et al. (247) reviewed a number of formulations showing an improved drug release. The preferred lipid excipient was Gelucire 44/14, which was extruded in a blend with 17 β-estradiol and PVP, PVA, or PEG 6000 (92). Mehuys et al. extruded Propranolol with HPMC and Gelucire 44/14, which was molded as core material in an ethyl cellulose pipe. The ethyl cellulose pipe offers protection against hydrodynamic and mechanical stress and provides a sustained, zero-order, erosion-controlled drug release and a better bioavailability in dogs compared to a commercial product (237, 297, 298). The application of extruded wax matrices for the retardation of drug release started in the early 1990s (299, 300). Sato et al. and Miyagawa et al. conducted a study to analyze the influence of dissolution rate-controlling agents on extruded carnauba wax matrices with diclofenac as model drug. Their investigations highlighted the importance of a proper pre-selection of the dissolution modifiers and their physicochemical properties (301, 302). Liu et al. prepared tablets from sustained-release extrudates of phenylpropanolamine, wax and different types of fillers and showed the effect on the dissolution rate caused by the type of filler in the matrix (303). This matches the investigations of De Brabander et al., who described a different impact on dissolution with different starch derivatives in extrudates compressed to mini tablets (304). Quintavalle et al. developed a sustained co-extrude with an inner hydrophilic core (PEG 6000) and an outer lipophilic coat both containing theophylline as drug. Its release was tailored through a suitable selection of parameters. In addition a very small in vivo bioavailability study of four healthy volunteers confirmed the desired sustained release (305). Roblegg et al. introduced vegetable calcium stearate for preparing sustained release pellets with a 20% paracetamol drug load. Although the addition of dissolution enhancers like glyceryl monostearate and tributyl citrate was able to reduce the process temperatures, the temperature of 70°C is still inappropriate for thermolabile substances (128). Vithani et al. successfully applied Compritol®

| Table IV (continued) |
|----------------------|
| Equipment            |
| Processing           |
| After melt extrusion the product is cooled and shaped downstream in further processing units, such as hot strand cutters, calendaring, chill rolls, or spheronizers/marumerizers (128, 280, 281, 290–294). |

Melt Extrusion is widely used for two main purposes, namely enhancing the bioavailability of poorly soluble drugs and the development of formulations with modified release profiles (294–296). Jannin et al. (9) and Keen et al. (247) reviewed a number of formulations showing an improved drug release. The preferred lipid excipient was Gelucire 44/14, which was extruded in a blend with 17 β-estradiol and PVP, PVA, or PEG 6000 (92). Mehuys et al. extruded Propranolol with HPMC and Gelucire 44/14, which was molded as core material in an ethyl cellulose pipe. The ethyl cellulose pipe offers protection against hydrodynamic and mechanical stress and provides a sustained, zero-order, erosion-controlled drug release and a better bioavailability in dogs compared to a commercial product (237, 297, 298). The application of extruded wax matrices for the retardation of drug release started in the early 1990s (299, 300). Sato et al. and Miyagawa et al. conducted a study to analyze the influence of dissolution rate-controlling agents on extruded carnauba wax matrices with diclofenac as model drug. Their investigations highlighted the importance of a proper pre-selection of the dissolution modifiers and their physicochemical properties (301, 302). Liu et al. prepared tablets from sustained-release extrudates of phenylpropanolamine, wax and different types of fillers and showed the effect on the dissolution rate caused by the type of filler in the matrix (303). This matches the investigations of De Brabander et al., who described a different impact on dissolution with different starch derivatives in extrudates compressed to mini tablets (304). Quintavalle et al. developed a sustained co-extrude with an inner hydrophilic core (PEG 6000) and an outer lipophilic coat both containing theophylline as drug. Its release was tailored through a suitable selection of parameters. In addition a very small in vivo bioavailability study of four healthy volunteers confirmed the desired sustained release (305). Roblegg et al. introduced vegetable calcium stearate for preparing sustained release pellets with a 20% paracetamol drug load. Although the addition of dissolution enhancers like glyceryl monostearate and tributyl citrate was able to reduce the process temperatures, the temperature of 70°C is still inappropriate for thermolabile substances (128). Vithani et al. successfully applied Compritol®
888 ATO as an excipient for the extrusion of the model drug diclofenac sodium and subsequent direct compression of sustained release tablets (306). Several investigations from the working groups of Breitkreutz and Kleinebudde et al. delivered insight into the applicability of different lipid excipients and the polymorphic behavior after melt extrusion and storage (43,131,142,159,161,163). Their storage stability studies revealed a superior stability of homogenous lipids (e.g., Dynasan 114) and emphasized the requirement for understanding and avoiding polymorphic transformation during storage (43,142). With Witocan 42/44 melt extrusion at room temperatures (“solvent-free cold extrusion”) and a stable release profile over storage was feasible (42,43). Another approach for reduction of the process temperature and extending the release was adopted by Schulze and Winter for a protein co-lyophilisate of INF α with hydroxypropyl-β-cyclodextrin in a lipid implant. The selective melting of a low melting lipid excipient in a blend with a high melting lipid provided an extrudable mass at moderate temperatures, an unchanged protein structure and avoided polymorphic changes of the high melting lipid due to recrystallization (207). In a second study with lysozyme Sax and Winter chose different low melting lipids in the combination with Dynasan 118 and different portions of pore forming agent to analyze the influence on the release kinetics of protein molecules from the lipid implant (45). The partial melting of the low melting fraction at incubation temperatures of 37°C built a protein reservoir and an additional non-aqueous diffusion pathway besides the conventional way through the buffer filled interconnected pore-network created by the dissolution of hydrophilic excipients (45,165). Recently, Oliveira et al. evaluated the extrudability of formulations, comprising Gelucire 33/01 and two further lipid excipients such as Dynasan 114, Precirol ATO 5, Witocan 42/44 or Compotril 888 ATO at room temperature and revealed a complex influence on porosity, thermal behavior, mechanical properties and dissolution rate depending on the chosen composition (307). It can be concluded that if lipid excipients are used, not only the dissolution rate but also mechanical properties and porosity should be monitored during storage. A list of formulations developed via extrusion and their characteristics are summarized in Table V.

All in all, lipid-based excipients usually show a lower melt viscosity and melting point compared to polymeric excipients typically used in hot melt extrusion (e.g., hydroxypropyl methylcellulose, cellulose acetate, polyethylene glycol) (294). Hence, with lipid excipients the addition of plasticizers (e.g., PEGs, triacetin, citric acid, GMS etc.) to decrease the glass transition point and melt viscosity is dispensable. This leads to a reduction of formulation complexity and allows for lower process temperatures (294,308,309). Thus, lipid excipients are able to extend the portfolio of suitable APIs for hot melt extrusion by also including heat sensitive candidates such as proteins (207). Another important issue in the recent years was the adjustment of the dissolution rate. Most of the published studies focus on sustained release formulations (128,142,303,306,310) but only a few on the application for taste masking by maintaining the immediate release profile (42,43,233,235) and enhancement of the solubility of poorly water-soluble drugs (92). The enhancement of the release profile was usually performed by adding rather high amounts of additives such as polyethylene glycol (161), or certain amounts of polymers such as PVP (92). However, the literature seems to lack in successful solvent-free melt extrusion approaches with lipid-based excipients alone, although hot melt extrusion with polymers is one of the most popular methods to enhance solubility (281). The reasons for the reluctant development of these kinds of formulations are multifactorial. The choice of lipid-based excipients for oral application suitable for this purpose is rather limited. The idea of including polyethylene groups is perhaps sufficient to increase the HLB and solubility, but leads to low melting temperatures (Gelucire 44/14—HLB 14, melting point 44°C) impeding melt processing (e.g., in spherization step) (92) and deteriorating formulation stability. Additionally, changes in polymorphism may occur and alter dissolution rates during storage (e.g., Gelucire 50/13—HLB 13, melting point 50°C) (311). Also other excipients such as sucrose esters, which would be stable up to 140°C (312) and are available with a promising high HLB of 16, showed polymorphic transformation during storage after melting (173). Polyglycerol esters crystallize in hexagonal subcells, exhibit no polymorphic transformation, are thermally stable below 100°C (312) and available in a HLB range from 6 to 11 (313). However, only one study published in 1993 could be found where these excipients were successfully applied in a spray chilling process (314).

**Melt Coating**

The first publication mentioning the term “melt coating” or more precisely “hot melt coating” was an US patent published in the year 1942 (315). A solvent-free coating technology was described to coat sheet material (e.g., paper, foil, metal) with molten thermoplastic resins, which can be used for the manufacturing of water- and grease-proof primary packaging of food (315,316). In the following decades the coating with molten lipid-based excipients became a standard procedure in the food industry (317,318). The literature discusses a wide range of food products coated by recrystallization of lipid-based molten excipients. For example: dip-coating of frozen meat (“larding”) (317,319,320), spray- or dip-coating as well as enrobing of ice cream with molten chocolate (321), spray chilling/congealing or fluidized bed coating of supplements (e.g., vitamin C) (322), food additives (e.g., aspartame) (323), flavors (324), or even heat sensitive probiotic bacteria (47,259), to name just a few. The advantages of this coating method have not gone unnoticed by the pharmaceutical industry. In the 1960s spray chilling was used for the first time by...
Merck & Co Inc. to achieve taste masking for iron particles (325) as well as for water-soluble vitamins (326). In 1968 Richardson Merrell Inc. applied sprays of molten resin mixtures on a tumbling bed of tablets in a pan coater (327,328), which marked the birth of the so called pan spray coating procedure. This technique was also transferred to a fluid bed coater, which was equipped with an additional heating system for the atomization air by Glatt Air Techniques Inc. in the early 1990s (62,329). This was the start of further research and development in this field, which has been reviewed in several articles (13,253,263,264,330,331). The fluidized bed coater, the pan coater and also the spouted bed are common machines used for hot melt coating (264,332–334). In a coating pan the molten material is either sprayed by a nozzle (pan spray (63,327,328)) or poured onto the rolling product (pan pour coating (113,167)). The same can be performed in a fluid bed chamber by fluidizing and melting the lipid excipient together with the product \textit{in-situ} hot melt coating/ solid dispersion fluid bed hot melt coating (123,147,335) or by spraying (hot melt spray coating (62,221)). Classically, the drug is preheated and fluidized in the fluid bed coater, but heat stable drugs can also be homogenously dispersed in the molten coating material and sprayed on fluidized nonpareils seeds (drug lipid dispersion hot melt coating (64–66)). This makes a time-consuming process step to obtain a core material with appropriate particle characteristics (e.g., size distribution, flowability, friability etc.) superfluous. Nevertheless, this method is only suitable for a small drug load as the solid amount in the spray dispersion can clog the nozzle during spraying. Drug-lipid interactions have to be evaluated in advance, as the drug may be dissolvable in the lipid matrix and can be present in the amorphous state after resolidification (65) posing a potential risk of formulation instability due to recrystallization during storage. Further, the particle size of the drug can have a significant impact on drug release (65) and therefore has to be observed during formulation development.

| Table V  | Overview: Selection of Formulations and Characteristics |
|----------|--------------------------------------------------------|
| API      | Lipids                                                 | Application/product characteristics                                      |
| Sodium benzoate (42) | Stearic acid, Precirol ATO 5, Witocan 42/44 | Taste masking  
Witocan 42/44 with superior binding capacity even at room temperature (cold extrusion)  
Solvent-based coating with Eudragit E required for taste masking  
Dynamas 114: porosity dependent on extrusion temperature (“blooming”)  
Precirol ATOS: alteration in dissolution rate during storage (“aging”) |
| Theophylline (142) | Precirol ATO 5, Dynasan 114 | Controlled release  
Dynamas 114: porosity dependent on extrusion temperature (“blooming”)  
Precirol ATOS: alteration in dissolution rate during storage (“aging”)  
Cold extrusion feasible for binary/terary mixtures of Witocan 42/44 and other lipids |
| Enrofloxacin (196) | Compritol 888 ATO/Aerosil 200 | Taste masking  
Original die diameter: impact on dissolution rate of very slightly soluble drugs  
Extrusion temperature: no impact on dissolution rate  
Immediate release (taste masking)  
Precirol ATOS: ageing during storage at elevated temperatures led to delay in dissolution rate |
| Sodium benzoate (43) | Witocan 42/44/Dynasan 114, Precirol ATO 5, Compritol 888 ATO | Controlled release  
Faster drug release from extrudates with Dynasan 114 in comparison to Precirol ATO 5  
Immediate release (taste masking) |
| Theophylline diprophylline (44) | Witocan 42/44, Precirol ATO 5, Dynasan 114 | Controlled release  
Immediate release (taste masking) |
| Theophylline (159) | Dynasan 112, Dynasan 116, Dynasan 118 | Controlled release  
Diffusion controlled and chain-length dependent dissolution rate; extrusion temperatures below melting point of instable α-form may induce storage instabilities |
| Theophylline (131) | Dynasan 118/Imwitor 491 | Controlled release  
Diffusion controlled dissolution, Imwitor 491 stabilizes the α-form and leads to storage instability due to transformation into the stable β-form and the formation of water repellent fractal structures |
| Theophylline (161) | Dynasan 116/polyethylene glycol 10000 | Controlled release  
Dissolution rate dependent on amount of additional polyethylene glycol 10000 amount; process temperatures above α-form avoid polymorphic transformation during storage |
| Trosinium chloride (163) | Dynasan 118 | Controlled release  
Extrudates show a fast initial and slower release over days. Tempered mini-molds have a negligibly initial drug release, an appropriate retardation and exhibit the stable polymorph. |
However, pouring techniques and in-situ hot melt coating are used more often in the context of research than in large-scale manufacturing. The use of pouring techniques in pan coating requires a high degree of attention and care, as poor execution may cause twinning as well as inferior coating homogeneity and efficiency (52). In-situ hot melt coating can be used without any additional hot-melt equipment (e.g., nozzle, heating system etc.), which may be advantageous for faster pre-studies. Nevertheless, the applicability in production scale is questionable, as core materials smaller than 420 μm are prone to agglomerate, porosity and particle size distribution affect batch-to-batch reproducibility and the lipid amount successfully applicable without agglomeration is rather low (<5%) and fails to reach the target specification (333). Hot melt spray coating requires more experience for the parameter selection, additional heating equipment, excipients with appropriate physicochemical characteristics (e.g., melting point, viscosity etc.) for the spraying process, and more time for the spraying step. Nevertheless, it is preferred over in-situ melting as it offers the option of fine adjustment of the product quality due to a higher number of process parameters, a lower risk of agglomeration, minor thermal stress of the API due to significant shorter exposure times to the molten coating, and easier up-scaling. Table VI provides a selection of formulations produced by spray coating and their intended purpose found in the literature.

Hot melt coating by direct blending is another method more recently mentioned in the literature (338,339). Drug granules or nonpareils are stirred in the molten coating or coating drug dispersion until homogeneity is reached and then congealed by cooling down to room temperature under continuous, vigorous stirring (37,339). A zero-order release was obtained by double coating of extruded acetaminophen pellets with carnauba wax and HPMC in the inner and Syncrowax HR-C (glyceril tribehenate) in the outer coating. HPMC and EC were described as useful swelling and eroding agents, which are able to decrease initial burst release by hindering drug diffusion (338). Further, sugar spheres with a coating comprising a waxy excipient with a low melting point and higher polarity (e.g., cetostearyl alcohol, Polawax, and 1-Monostearin) and a low drug load of acetaminophen exhibited an immediate release profile. At the first glance, the processing seems very convenient and easily controllable for particles with an appropriate size (250–595 μm) without the requirement of any sophisticated equipment in laboratory scale (37), but if and how this method is suitable for up-scaling has yet to be evaluated. It will also be of further interest, if taste masking can be attained by this approach, how the dissolution profile can be tailored by different pellet and coating compositions (e.g., other drugs, higher drug load, multi-layers) and most importantly if the obtained formulations are stable during storage.

As already stated in the subchapter on hot melt extrusion, controlled release was the main application purpose for hot melt coating with lipid-based excipients. Rosiaux et al. gave a comprehensive insight into the literature on drug release mechanisms of sustained release lipid matrices (26). Immediate release was achieved with a homogenous mixture of a lipid excipient with a rather low HLB (HLB ≤ 5), a higher melting point (≥60°C), a small recrystallization range (≤35°C) and a hydrophilic polymer or emulsifier with sufficient miscibility in the melt (e.g., hydroxyethyl cellulose, hydroxypropyl cellulose, carbomer, PEG-derivatives, E-400–E-499 etc.) (40,336). The emulsifiers and disintegrants were mainly selected on the basis of their HLB and hydrophilic behavior, but only one study is known in which the emulsifier was used as a polymorphic modifier to gains the stable β-phase during and directly after the process (162). Although studies on storage stability are the most crucial point while working with lipid based formulations, in particular if complex coating compositions are used, only very few studies have taken this point into account (40,46,162). The same holds true for the evaluation of taste masking, which often is a further target of this kind of formulation. Sufficient taste masking is often assumed on the basis of the release profile in the first minute of dissolution, but only rather seldom volunteers or more sophisticated analytical tools are used for the evaluation (40).

Melt Agglomeration

Melt agglomeration includes melt granulation and melt pelletization, which provides highly spherical agglomerates with a narrow size distribution and a particle size from 0.5 to 2 mm. However, both terms cannot be clearly distinguished and are not used consistently in the published literature (340,341). Apart from using a melt extruder equipped with the necessary accessories, the formation of granules and pellets can be performed in a fluid bed (84,124,342,343) or high shear mixer (55,75,81,99,130,148,169,344). Schaefer et al. gave a deep insight into the important process parameters especially for the high shear mixer and described the following phases and mechanisms during agglomeration (125,345–350).

1. Nucleation phase (345,346,351,352):

In the first step the solid lipid binder is either filled into the equipment together with the starting material consisting of excipients (e.g., filler, disintegrants etc.) and/or drug or molten externally with or without the drug. In case the binder is molten during mixing with the remaining compounds the method is described as “melt-in” (high shear mixer) or also “in-situ” (fluid bed) agglomeration. If the binder is added in the molten form it can either be sprayed with a nozzle onto the preheated material in the “spray on”-method or steadily pumped onto the preheated material in the “pour-on” or “pump-on”
method. Two different nucleation mechanisms after wetting of the material have been postulated. One is the distribution mechanism where the molten binder spreads over the surface of the starting material and primary nuclei are formed by coalescence. The other is the immersion mechanism, which is predominant if the molten binder droplets are larger than the starting material particles and the solid particles immerse into the molten droplet surface to form the nuclei. The droplet size can be affected by the shear rate (melt-in, pour-on), the initial particle size of the lipid binder (melt-in), the spray rate and pressure (spray-on), as well as by the binder viscosity at the applied temperature. The nucleation takes place as long as nuclei interact with initial particles. This leads to a depletion of fines and finally to an increased wetting and starting of growth by coalescence between nuclei.

2. Growth phase (345,346,351,352):

The growth phase presents an equilibrium between consolidation and growth until a critical size is reached and attrition and breakage into smaller particles takes place. The critical size depends on several parameters such as the physicochemical properties and amount of the binder (e.g., particle size, viscosity, deformability, temperature etc.), characteristics of the starting material (particle size, shape, density etc.) and kinetic energy applied (impeller speed and frictional heat, air temperature) (346,351,352). Parameters such as the particle size and shape, the binder viscosity and a certain solid/lipid ratio

| Table VI | Overview: Selection of Formulations and Characteristics |
| --- | --- |
| API | Coating agent | Characteristics/application |
| Acetaminophen | Carnauba wax/sorbitan monostearate, Hydrogenated vegetable oils/sodium stearoyl lactate or sorbitan monostearate or glyceryl monostearate (46) | Taste masking, immediate release, storage stability achieved with carnauba wax, formulation with hydrogenated vegetable oils with inferior storage stability |
| | Compritol 888 ATO (152) | Controlled release (Higuchi model) |
| | Precirol ATO S, stearic acid | Immediate release |
| | Compritol 888 ATO | Taste masking assumed, only study of release profile, no study for taste masking or formulation stability included |
| | Several combinations with surfactants and/or release enhancer were tested: CaCO₃, PEG 3000, PEG 4000, Amberlite IRP, Tween 20, Cremophor EL, Cremophor A6, Gelucire 50/13, Kollidon CL-M, Kollidon CL, Carbowax 971P NF, Carmellose Sodium, KHCO₃, Lactose, Blanose (336) | |
| N-acetylcysteine (162) | Tripalmitin/Polysorbate 65 | Immediate release, taste masking (volunteer panel), stability achieved, acceleration of α→β transition due to emulsifier |
| Antibiotics (40) | Carnauba wax/carboxer, xanthan gum, L-HPC | Immediate release, taste masking (electronic tongue), storage stability achieved |
| | Bees wax/cetyl alcohol | Taste masking (human volunteers) |
| | Compritol 888 ATO | Stability not approved |
| Chloroquine (145) | Stearic acid, palmitic acid | Controlled release |
| Diclofenac sodium (111) | Glycerol monostearate/bees wax/ white wax/ stearyl alcohol | Immediate release, taste masking was assumed (drug release after 1 min) |
| Diltiazem HCl (337) | Stearic acid/ PEG 6000 | Immediate release, moisture sorption control, stability not approved |
| Herbal extract (115) | Steric acid/ PEG 6000 | Immediate release, taste masking and stability not approved |
| Ibuprofen | Precirol ATO S (27) | Controlled release |
| | Compritol 888 ATO (146) | Maturing reduced and stabilized dissolution rate |
| Metoprolol tartrate (34) | Bees wax/ethyl cellulose (34) | Sustained release, stable during storage |
| | Compritol 888 ATO | Controlled release |
| | Hydrogenated castor oil/HPMC, sodium laurel sulphate (52) | Hydrophilic pore formers increased the release, no stability study conducted |
| Theophylline | Compritol 888 ATO (143,144,146) | Controlled release |

1532 Becker, Salar-Bezhadi and Zimmer
also have an effect on the granule strength and whether agglomerates are formed and densified by coalescence or if fragmentation and layering on the existing agglomerates is present. In case the binder viscosity and lipid/solid ratio are well-chosen, densification and a steady growth will take place and depending on the binder amount and the applied shear force, particle size distribution narrows, sphericity increases and porosity decreases (melt pelletization).

3. Cooling phase (81,352)

The cooling phase can be performed by cooling the particles in the equipment, which is much faster in the spray-on compared to the high shear mixer due to the better heat transfer, or by rapid cooling by pouring the material directly into liquid nitrogen (“flash-cooling”) or by simply spreading the material out on thin layers on trays (high shear mixer). In case of polymorphic material or material that can vary in the degree of its crystallinity (e.g., PEG 3000), the cooling rate can play an essential role in controlling formulation stability and drug release (81). Table VII lists a selection of formulations prepared by melt agglomeration in a high shear mixer and fluid bed.

Several designs have been applied to understand the granulation mechanisms and the effect of different process parameters on product quality (71,99,118,198,274,337). Comparison studies using in-line particle size measurement tools (focused beam reflectance measurement, spatial filter velocimetry) or by endpoint determination between the binder application methods (melt-in/in-situ, spray-on) revealed that the results were comparable in respect of particle size distribution and flowability. The dissolution profiles of the granules processed in a fluid bed and in a high shear mixer were comparable, provided the drug was applied in the same close contact to the lipid excipients (126,277). Further studies revealed that both fluid bed methods, spray-on as well as in-situ, were able to obtain smooth and spherical granules with a comparably fast dissolution rate for granules of the same size, while the particle size distribution seems to be positively affected by smaller binder particles or droplets in both methods (354). Studies revealed that melt agglomeration in a fluid bed can be successfully applied to improve the lubricant performance, flowability, and compressibility of the granules in a subsequent tableting step (358,359). This is caused by a homogenous repartition and due to the significantly lower shear force in a fluid bed than in a high shear mixer that leads to a reduction of particle densification and to an increased elastic deformation and better compressible granules (124). Moreover, the fluid bed offers a more efficient cooling process without additional densification, which is an advantage for up-scaling and enables the addition of higher binder contents (343). Further, Kukec et al. were able to successfully scale an in-situ laboratory method up to pilot scale by the aid of a three-factor, five-level circumscribed central composite design, whereby the resulting dissolution rate was affected mainly by the binder content (261). Hence, in-situ melt fluid bed granulation is a viable and fast method to obtain granules from heat sensitive drugs.

Other Methods

Spray Congealing (Synonyms: Spray Chilling, Spray Cooling)

Although spray congealing is often listed as a melt agglomeration technique (340,352,360), it can be seen as a mix of all three aforementioned methods, as the products are perfectly spherical microspheres or microcapsules that can contain the drug embedded as a solid dispersion in the lipid matrix. The nozzle type and fluid delivery determines whether a matrix (“microsphere”) or a more core/shell-like structure (“microcapsules”) of the drug embedment is generated. Prilling is a special form of spray-congealing that delivers a product with an increased particle size of 500 to 2000 μm (“prills”) (120,157,361). For spray congealing a stable and homogenous mixed melt dispersion of the drug (and further excipients if necessary) is required. The chosen technique (e.g., ultrasound homogenizer, high shear mixer) for the preparation of the dispersion may have a significant impact on the rheological behavior, particle size and crystallinity and should be therefore controlled during product development and processing (76). This mixture is subsequently processed in a choice of atomization units, which are distinguished by their atomization mechanism, liquid channeling, throughput and product properties (e.g., particle size and distribution, structure etc.) (285,286). Examples mentioned in the literature are the spinning disk (127,132,362,363), vibrating nozzle (157,361), pneumatic nozzle (101,120,364,365), ultrasonic devices (72,77,78,366–368), or dual-fluid nozzle (73,76). After atomization the particles are solidified by falling in a large prilling tower, a chamber of a spray dryer flushed with cold air, liquid nitrogen or a carbon dioxide ice bath (285,364). This step is critical especially if greater particles like prills have to be solidified, which may lead to deformation or sintered lipid blocks in the product container due to an inappropriate time of flight and an incomplete recrystallization. Table VIII gives an overview of some formulation characteristics obtained with spray congealing.

An important point to consider while working with the spray congealing technique is the polymorphic state of the obtained microspheres. As rapid cooling is applied, thermodynamically unstable forms crystallize during the resolidification step. Even microspheres with carnauba wax, which is often stated to be a non-polymorphic material (40,46,221), showed thermal transition events in a microcalorimetric system during storage. However, the effects on parameters such...
as the dissolution rate were not evaluated (362). A clear polymorphic change was detected with tripalmitin-insulin microspheres, which showed the unstable α-form after resolidification and transformed into the stable β-form within 28 days of storage (365). Yajima et al. discovered that the transformation of the α-form of the freshly spray congealed glycerol monostearate Eudragit E microspheres to more stable polymorphic forms had a significant impact on the drug release in a mini-column method used for testing taste masking efficiency (202). Li et al. observed that the drug Bupivacaine as well as

| Table VII | Selection of Formulations Produced by Melt Agglomeration Techniques |
| --- | --- |
| High shear mixer | API Exipients Application |
| Acetaminophen | Glycerol monostearate/ aminoalkyl methacrylate copolymer E (353) PEG-6-stearate (169) pH-dependent drug release (appropriate for taste masking) | |
|  | Stearic acid (187,188,274) Sustained release | |
| Diazepam (81) | Gelucire 50/13 Dissolution enhancement | |
| Dipeptidylpeptidase IV Inhibitor (56) | Hydrogenated castor oil Moisture protection, maintained immediate release | |
| Lansoprazole (71,75) | Gelucire 44/14, Gelucire 50/13 Dissolution enhancement | |
| Griseofulvin (99) | Gelucire 44/14 Dissolution enhancement | |
| Fluid bed | API excipients Application |
| acetaminophen | Precirol ATO 5 (198) Taste masking | |
|  | Gelucire 50/13 (354, 355) Immediate release | |
|  | Gelucire 50/13 Immediate release | |
| Ibuprofen (356) | Precirol ATO 5/Gelucire 54/02 Controlled release and lubrication in-situ | |
| Lu-X (84) | Glycerol monolaurate, Gelucire 50/13 Dissolution enhancement | |
tristearin crystallize in their unstable form during spray congealing and the transformation into their stable forms during heat-treatment has a significant impact on the fluidity and gelation behavior in an aqueous medium (363). Although Gelucire 50/13 was able to enhance the dissolution rate of Piroxicam in spray congealed microspheres significantly, the morphological structure changed from a smooth surface to a flake-like structure (bloom) and the dissolution rate increased during storage (30°C/1 month) (80). Additionally, the drug showed a remarkable impact on the polymorphic transformation behavior, for instance, paracetamol was able to stabilize the low melting lipid fraction while caffeine was associated with the transformation to more stable phases (74). Moreover, different polymorphic forms can exhibit a different potential to incorporate drugs in a molecular dispersed form, and therefore changes in lipid polymorphism during storage can lead to drug precipitation and changes in dissolution rate (214). But also the crystallinity and polymorphic state of the drug are important, as melting techniques are able to generate an amorphous state of the drug or reduce crystallinity or have an effect on the recrystallized polymorph of the drug (120,364,369). Hence, studies on polymorphism and drug/lipid interactions are crucial for formulation development.

**Freeze Pelletization**

Freeze pelletization is a variant of the spray congealing process. The molten dispersion is dropped into a column with a cooling liquid with a needle or nozzle (121,249,370). The liquid offers a better heat transfer than the air and the resulting pellets are described as nonporous, spherically shaped and exhibiting a narrow size distribution (370). Nevertheless, the selection of a suitable cooling fluid seems to be a great challenge, as it has to be non-toxic, inert, immiscible and has to have an appropriate viscosity (370).

**Pastillation**

Pastillation is a method to facilitate the handling with dusty hazardous powders by transforming them into pastilles common in the petro- and agrochemical industry (250). In this process the molten drug/lipid dispersion is dropped with a needle on a cold surface. An important parameter is the contact angle of the solidified drop to the surface, which affects the flowability of the pastilles and can be adjusted by the needle height and geometry as well as with the temperature of the surface (250,371,372). As the up-scaling to continuous manufacturing seems to be rather easy and different lipid materials should be applicable, this method seems to be

### Table VIII  Selection of Formulations Produced by Spray Congealing

| API                  | Lipid excipients         | Characteristics                                                                 |
|----------------------|--------------------------|-------------------------------------------------------------------------------|
| Acetaminophen (127)  | Glycerol monostearate    | pH-dependent release (taste masking)                                          |
|                      |                          | Box–Behnken design                                                           |
|                      |                          | Inputs: drug load, Eudragit E amount                                          |
|                      |                          | Mean size: 400 μm                                                             |
|                      |                          | Drug: 10–30%                                                                 |
| Glimepiride (73)     | Gelucire 50/13           | Dissolution enhancement                                                       |
|                      |                          | Morphological changes (“bloom”) during storage (30°C/1 month)                 |
|                      |                          | d$_{50}$: 58–278 μm                                                           |
|                      |                          | Drug: 1.7% (w/w)                                                             |
| Meloxicam (101)      | Gelucire 44/14           | Dissolution enhancement                                                       |
|                      |                          | Drug load: ~ 10%                                                              |
| Mesalazine (36)      | Carina wax, stearic acid | pH-dependent release                                                          |
|                      |                          | Two step congealing process                                                   |
|                      |                          | 1. carina wax/drug reservoir                                                  |
|                      |                          | 2. stearic acid enteric coating                                                |
|                      |                          | Drug load: ~ 18%                                                              |
| Metoprolol tartrate (120) | Stearic acid, behenic acid | Sustained pH-dependent release                                                |
|                      |                          | Prilling: 1.8–2.5 mm                                                          |
|                      |                          | Drug load: 10–40%                                                            |
|                      |                          | Polymorphism of fatty acids not affected                                      |
|                      |                          | Drug/lipid interaction, amorphous fraction recrystallized during storage at accelerated conditions |
|                      |                          | In vivo results comparable with commercial formulation                        |

Lipid-based Solid Oral Formulations
promising for the pharmaceutical industry, provided recrystallization behavior and Reynolds number are appropriate (371).

**Fusion (Synonyms: Hot Fusion, Melt Fusion, Melt-Mixing) and Melt-Solidification**

The term “hot fusion” refers to the preparation of a solid dispersion of a drug in a matrix and therefore can be understood as a kind of melt extrusion but with the use of less sophisticated equipment on a laboratory scale and has often been applied in pre-formulation studies. Hot fusion is performed by melting the lipid excipient and mixing the drug homogenously by using a magnetic stirrer, a high shear mixer or rotor-stator homogenization to generate a solid dispersion or even a solid solution (29,32,85,133,369). The molten mixture can be molded into tablets (68,373–375), filled in capsules (102,139), poured into a cold water bath and stirred to obtain beads (110,376,377), screened through a sieve for generating granules (32,378), spheronized to pellets (49), or ground and sieved (48,114,136,153,172). The sieved material may be used for direct compression to tablets (32,48,114,136,153,158,169,172,379). The fusion of highly soluble drugs with hydrophobic matrices (e.g., Compritol 888 ATO, glyceryl monostearate, stearic acid, Precirol ATO 5, hydrogenated castor oil etc.) retards the drug release (29,48,114,136,251) and tableting of this solid dispersion has a significantly higher efficiency to sustain release than the direct compression of the physical mixture (29,136,153,210,379). The dissolution of poorly water soluble drugs may be significantly enhanced in a solid dispersion with hydrophilic lipid excipients, such as Gelucire 50/13 (85), Gelucire 44/14 (89,93) compared to the physical mixture of the same (85,93). The addition of an effervescent formulation to the tablets can also help overcome the slower release of tablets compared to an according multiparticulate system (89).

**Sintering of Tablets**

Thermal treatment (“sintering”) of tablets received by direct compression of the physical mixtures had a significant retarding effect on the dissolution rate due to a redistribution of the wax and an increased matrix tortuosity (158,380,381). However, with hydrogenated cotton seed oil the opposite effect has been seen, which was assumed to be a consequence of wax migration (379). As the study lacks solid-state analysis data a change in polymorphic and morphological properties cannot be excluded (379).

**CONCLUSION**

Solvent-free melting techniques are well-known in the literature and very promising for the pharmaceutical industry. The achievable formulation properties serve a wide-area, ranging from modified release by allowing different dissolution kinetics, but also bioavailability enhancement (e.g., gastroretentive formulation), taste masking, up to moisture protection and improvement of swallowability. A recent trend is the design of multiparticulate drug delivery systems, which strike a good and balanced compromise between taste masking and fast release. These systems play a key role in the development of population driven patient-centric strategies, improving the adherence to medication for swallowing difficulties in pediatrics and geriatrics (382). An ongoing challenge in working with lipid materials is the proper handling of stability issues such as polymorphic and morphological changes. Meeting this challenge is worth the effort: the materials required are often cheaper than the corresponding polymers and are mostly processable in standard industrial equipment such as the high shear mixer or fluid bed coater. This facilitates the decision for feasibility studies utilizing a solvent-free melting process in formulation development. Therefore, solvent-free melting processes offer an effective, simple, safe and eco-friendly way of manufacturing in pharmaceutical and food industries.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**REFERENCES**

1. Schwartz JB, Simonelli AP, Higuchi WI. Drug release from wax matrices I. Analysis of data with first-order kinetics and with the diffusion-controlled model. J Pharm Sci. 1968;57(2):274–7.
2. Lantz RJ, Robinson MJ. Method of preparing sustained release pellets and products thereof. US3146167 A; 1964.
3. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.
4. Kalezpu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems - an overview. Acta Pharm Sin B. 2013;3(6):361–72.
5. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667–76.
6. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 2004;30(5):429–48.
7. Dubey R, Shami TG, Bhasker Rao KU. Microencapsulation technology and applications. Def Sci J. 2009;59(1):82–93.
8. Singh MN, Hemant KSY, Ram M, Shivakumar HG. Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci. 2010;5(2):65–77.
9. Jamniz V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):734–46.
10. Freitas C, Müller RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm. 1998;46(2):145–51.
11. Bagaria SC, Lordi NG. Aqueous dispersions of waxes and lipids for pharmaceutical coating. US5023108 A; 1991.
12. Chauhan B, Shimp S, Paradkar A. Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique. AAPS PharmSciTech. 2003;6(3):E405–9.
13. Bose S, Bogner RH. Solventless pharmaceutical coating processes: a review. Pharm Dev Technol. 2007;12(2):115–31.
14. Groe M, Müllertz A. Liquid self-microemulsiﬁng delivery systems. In: Hauss DJ, editor. Oral liquid-based formulations: enhancing the bioavailability of poorly water-soluble drugs. Boca Raton: CRC Press Taylor & Francis Group, LLC; 2007. p. 107-128.
15. Müller RH, Lippacher A, Gohla S. Solid lipid nanoparticles (SLN) as a carrier system for the controlled release of drugs. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker Inc; 2000. p. 377-392.
16. Walch J, Cram A, Woertz K, Breitkreutz J, Winzenburg G, Turner R, et al. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients. Adv Drug Deliv Rev. 2014;73:14–33.
17. Shrestha H, Bala R, Arora S. Lipid-based drug delivery systems. J Pharm. 2014;doi:10.1155/2014/801820.
18. Cannon JB, Shi Y, Gupta P. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery - part II: oral applications. In: Liu R, editor. Water-insoluble drug formulation. Boca Raton: CRC Press Taylor & Francis Group, LLC; 2009. p. 195-226.
19. Wasan KM. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev Ind Pharm. 2001;27(4):267–76.
20. Sanches-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients peceol and gelucire 44/14 decrease P-glycoprotein mediated eﬄux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within caco-2 cells. J Pharm Pharmacol. 2007;10(3):319–31.
21. Ingelman-Sundberg M, Simn SC, Gomez A, Rodriguez-Antonia C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacocoeagnostic and clinical aspects. Pharmacol Ther. 2007;116(3):496–526.
22. Griffin WC. Classiﬁcation of surface-active agents by “HLB”. J Soc Cosmet Chem. 1949;1(5):311–26.
23. Kanicky JR, Lopez-Montilla J-G, Pandele S, Shah DO. Surface chemistry in the petroleum industry. In: Holmberg K, editor. Handbook of applied surface and colloid chemistry. New York: Wiley; 2001. p. 251-267.
24. Shah MH, Paradkar A. Eﬀect of HLB of additives on the properties and drug release from the glyceryl monostearate matrices. Eur J Pharm Biopharm. 2007;63(3):331–9.
25. Le HT. Preparing sustained release dosage forms of nifedipine by hot-melt coating method. Master Thesis; Oregon State University, Corvallis, 2004.
26. Uhumwangho MU, Okor RS. Eﬀect of matrix granulation and wax coating on the dissolution rates of paracetamol granules. Afr J Biotechnol. 2006;5(9):766–9.
27. Uhumwangho MU, Okor RS. Modiﬁcation of drug release from aceterminogranules by melt granulation technique - consideration of release kinetics. Pak J Pharm Sci. 2006;19(1):22–7.
28. Ziegler I, Jacobs I. Coated pellets. US8147874 B2; 2008.
29. Sudke SG, Sakarkar DM. Application of hot-melt coating for sustained release pellets of fenofenine. Der Pharm Sin. 2014;3(4):153–9.
30. Breitkreutz J, El-Saleh F, Kiera C, Kleinebudde P, Wiese W. Pediatric drug formulations of sodium benzozate: II. Coated granules with a lipophilic binder. Eur J Pharm Biopharm. 2003;56(2):255–60.
31. Krause J, Thommes M, Breitkreutz J. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion. Eur J Pharm Biopharm. 2009;71(1):138–44.
32. Reitz C, Strachan C, Kleinebudde P. Solid lipid extrudates as sustained-release matrices: the effect of surface structure on drug release properties. Eur J Pharm Sci. 2008;35(4):335–43.
33. Sax G, Winter G. Mechanistic studies on the release of lysosome from twin-screw extruded lipid implants. J Control Release. 2012;163(2):187–94.
34. Johnson WM, Reo JP. Tastemasked pharmaceutical system. US5891476 A; 1999.
35. Mogna G, Strozzi GP, Mogna L. Food product comprising probiotic bacteria coated with a coating of vegetable origin. EP2544547 A1; 2011.
36. Abdelkader H, Abdalla YA, Salem H. Formulation of controlled-release tablets of diclofenac sodium by melt granulation technology. Int J Pharm. 2000;136(2):119–29.
37. Padsalgi A, Bidkar S, Jadhav V, Sheladaya D. Sustained release tablets of theophylline by hot melt wax coating technology. Asian J Pharm. 2008;2(1):26–9.
asound-assisted atomization. J.  

53. Macerina T, Oawa T, Nakajima K, Kobayashi M. Preparation of spherical beads without any use of solvents by a novel tumbling melt granulation (TMG) method. Chem Pharm Bull. 1997;45(3):518–24.

54. Bechler J, Chauhan S, France G. Cimetidine granules coated with a partially hydrogenated vegetable oil. US5597844 A; 1997.

55. Heng PWS, Wong TW, Cheong WS. Investigation of melt agglomeration process with a hydrophobic binder in combination with sucrose stearate. Eur J Pharm Sci. 2003;19(3):381–93.

56. Jozwiakowski MJ, Jones DM, Franz RM. Characterization of a hot-melt fluid bed coating process for fine granules. Pharm Res. 1996;13(7):1119–26.

57. Bequette R, Bonenberger BA, Gallian CE, Reckelhoff J. Direct compression cholesterylamine tablet and solvent-free coating therefore. US5455047 A; 1995.

58. Chansanroj K, Betz G. Improving stability of triglycerides in hot melt coating formulations. Glatt Int Times. 2008;26:1-6.

59. Chansanroj K, Betz G, Leuenberger H, Mitrevej A, Sinchaipanid N. Development of a multi-unit floating drug delivery system by hot melt coating technique with drug-lipid dispersion. J Drug Delivery Sci Technol. 2007;17(5):333–8.

60. Chansanroj K, Betz G, Leuenberger H, Mitrevej A, Sinchaipanid N. Polymorphic change of a triglyceride base in hot melt coating process and stability acceleration by tempering process. J Drug Delivery Sci Technol. 2007;17(3):347–52.

61. Kakiguichi Y, Miyawaki M, Yokota K. Process for producing coated tablets. US5455047 A; 1995.

62. Jatwani S, Rana AC, Singh G, Aggarwal G. Solubility and dissolution of immediate release lansoprazole pellets produced by melt pelletization. Pharm Ind. 2008;70(1):147–55.

63. Martins RM, Siqueria S, Machado MO, Freitas LA. The effect of homogenization method on the properties of carbamazepine micro particles prepared by spray congealing. J Microencapsul. 2013;30(7):692–700.

64. Passeri N, Albertini B, Perussuti B, Rodriguez L. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int J Pharm. 2006;318(1-2):592–102.

65. Passeri N, Perussuti B, Moregmini M, Voinovich D, Albertini B, Cavalliri C, et al. Characterization of carbamazepine-gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasonounds. J Pharm Sci. 2002;91(3):699–707.

66. Pongjanyakul T, Mediocc NJ, Tucker IG. Melted glycercyl palmitostearate (GPS) pellets for protein delivery. Int J Pharm. 2004;271(1-2):53–62.

67. Qij S, Marchaud D, Craig DQ. An investigation into the mechanism of dissolution rate enhancement of poorly water-soluble drugs from spray chilled gelucire 50/13 microspheres. J Pharm Sci. 2010;99(1):262–74.

68. Seo A, Holm P, Kristensen HG, Schafer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. Int J Pharm. 2003;259(1-2):161–71.

69. Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. Stabilization and improved in vivo performance of amorphous etoricoxib using gelucire 50/13. Pharm Res. 2005;22(10):1727–34.

70. Upadhyay P, Pandit JK. Formulation of fast-release gastroretentive solid dispersion of glibenclamide with gelucire 50/13. Int J Pharm Res. 2012;11(3):361–9.

71. Vilhelmson T, Eliassen H, Schafer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int J Pharm. 2005;303(1-2):132–42.

72. Vippagunta SR, Mual KA, Tallavajhala S, Grant DJW. Solid-state characterization of nifedipine solid dispersions. Int J Pharm. 2002;236(1-2):111–23.

73. Ahuja N, Kature OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm. 2007;65(1):26–38.

74. Barker SA, Yap SP, Yuen KH, McCoy CP, Murphy JR, Craig DQ. An investigation into the structure and bioavailability of alphatocopherol dispersions in gelucire 44/14. J Control Release. 2003;91(3):477–86.

75. Barnwell SG, Higginbottom S, Whelan IP, Burns SJ. Pharmaceutical formulations. US6613353 B1; 2003.

76. Da Fonseca Antunes AB, De Greest BG, Vervaet C, Remon JP. Gelucire 44/14 based immediate release formulations for poorly water-soluble drugs. Drug Dev Ind Pharm. 2013;39(5):791–8.

77. Damian F, Blaton N, Naens L, Balzarini J, Kinget R, Augustijns P, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and gelucire 44/14. Eur J Pharm Sci. 2000;10(4):311–22.

78. El Massik MA, Abdallah OY, Galal S, Daabas NA. Semisolid matrix filled capsules: an approach to improve dissolution stability of phenytoin sodium formulation. Drug Dev Ind Pharm. 2003;29(5):531–43.

79. Hulsmann S, Backensfeld T, Keitel S, Bodmeier R. Melt extrusion – an alternative method for enhancing the dissolution rate of 17β-estradiol hemihydrate. Eur J Pharm Biopharm. 2000;49(5):237–42.

80. Jatwani S, Rana AC, Singh G, Aggarwal G. Solubility and dissolution enhancement of simvastatin using synergistic effect of hydrophilic carriers. Der Pharm Lett. 2011;3(6):280–93.

81. Karatas A, Yüksel N, Baykara T. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol. Farmaco. 2005;60(9):777–82.
95. Khoo SM, Porter CJH, Charman WN. The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid-based solid dispersions: physical stability and absolute bioavailability assessment. Int J Pharm. 2000;205(1-2):65-78.

96. Parmar N, Bagda A, Patel M, Patel S. Formulation strategy for dissolution enhancement of simvastatin. Int J Pharm Sci Res. 2012;3(10):3817-22.

97. Siripuram PK, Bandari S, Jukanti R, Veerareddy PR. Formulation and characterization of floating gelucire matrices of metoprolol succinate. Dissolution Technol. 2010;17(3):34-9.

98. Soliman MS, Khans MA. Preparation and in vitro characterization of a semi-solid dispersion of flurbiprofen with gelucire 44/14 and labrasol. Pharmazie. 2005;60(4):288-93.

99. Yang D, Kulikarni R, Behne RJ, Kotiyani PN. Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. Int J Pharm. 2007;329(1-2):72-80.

100. Yukel N, Karatas A, Ozkan Y, Savaser A, Ozkan SA, Baykara T. Enhanced dissolution of piroxicam using gelucire 44/14 and labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2005;56(3):453-9.

101. Zaky AA, Abdel-Raheem IT. Solubility enhancement of meloxicam prepared via binary and ternary phases using spray congealing. Asian J Pharm Health Sci. 2011;1(4):196-203.

102. Chauhan B, Shinpi S, Mahadik K, Paradkar A. Preparation and evaluation of floating riserdronate sodium gelucire 39/01 matrices. Acta Pharm. 2004;54(3):205-14.

103. Juarez-Sobanet D, Villafuerte-Robles L. Gelucire 39/01 as excipient for gastroretentive metronidazole sustained delivery. Int J Pharm Sci. 2011;2(3):86.

104. Shah SH, Patel JK, Patel NV. Floating multiple unit lipid granules of gatifloxacin-gelucire 39/01: formulation optimization using factorial design. Asian J Pharm Sci. 2010;5(1):35-43.

105. Patel DM, Patel NM, Patel VF, Bhatt DA. Floating granules of ranitidine hydrochloride-gelucire 43/01: formulation optimization using factorial design. AAPS PharmSciTech. 2007;8(2):Article 30.

106. Rao MEB, Swain SS, Patra CN, Satt J, Patra S. Development and in vivo evaluation of floating multiparticulate system of repaglinide. FABAD J Pharm Sci. 2011;36(2):75.

107. Shinpi S, Chauhan B, Mahadik KR, Paradkar A. Preparation and evaluation of diltiazem hydrochloride-gelucire 43/01 floating granules prepared by melt granulation. AAPS PharmSciTech. 2004;5(3):51-6.

108. Chorro D, Rial L, Vila Jato JL. Aging of sustained-release formulations of amoxicillin and gelucire 64/02. Drug Dev Ind Pharm. 1993;19(4):473-82.

109. Yang X, He H, Meng J, Zhang C, Hong M, Tang X. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion/ characterization of floating gelucire matrices of metoprolol succinate. Dissolution Technol. 2010;17(3):34-9.

110. Parmar N, Bagda A, Patel M, Patel S. Formulation strategy for dissolution enhancement of simvastatin. Int J Pharm Sci Res. 2012;3(10):3817-22.

111. Chauhan B, Shinpi S, Mahadik K, Paradkar A. Preparation and evaluation of floating riserdronate sodium gelucire 39/01 matrices. Acta Pharm. 2004;54(3):205-14.

112. Qi S, Deutsch D, Craig DQM. An investigation into the interaction mechanisms. Int J Pharm. 2007;329(1-2):72-80.

113. Patil AT, Khobragade DS, Chafle SA, Ujjainkar AP, Umathe SN, Adhvaryu P. Development of sustained-release lipophilic calcium stearate pellets by melt pelletisation. Int J Pharm. 2000;205(1-2):65-78.

114. Sudke SG, Sakarakat DM. Design and characterization of enteric coated pellets of aspirin using hot-melt coating technique. Int J Pharma Res Rev. 2013;2(3):1-10.

115. Bhagwat DA, Kavitskwar PS, Sakarakat DM. Sustained release matrices of verapamil HCl using glyceryl monostearate and stearic acid. Res J Pharm Technol. 2008;1(4):405-9.
and Compritol 888 ATO-5. Int J Pharm. 2006;309(1-2):688.

141. Reitz C, Kleinebudde P. Influence of thermal and thermo-physical characterisation of Precirol® and Compritol® as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm. 2003;260(1):47-57.

142. Hamdani J, Moës AJ, Amighi K. Development and evaluation of prolonged release pellets obtained by the melt pelletization process. Int J Pharm. 2002;251(1-2):167-77.

143. Jannin V, Pochard O, Chambin O. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol® ATO 5. Int J Pharm. 2006;309(1-2):6-15.

144. Rao M, Ranpise A, Borate S, Thanki K. Mechanistic evaluation of the effect of sintering on Compritol® 888 ATO matrices. AAPS PharmSciTech. 2009;10(2):355-60.

145. Reitz C, Kleinebudde P. Influence of thermal and thermo-mechanical treatment. J Therm Anal Calorim. 2007;89(3):669-73.

146. Reitz C, Kleinebudde P. Solid lipid extrusion of sustained release dosage forms. Eur J Pharm Biopharm. 2007;67(2):440-8.

147. Barthelemy P, Lafort JP, Farah N, Joachim J. Compritol® 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm. 1999;47(1):87-90.

148. Faham A, Prinderre P, Farah N, Eichler KD, Kalantzis G, Joachim J. Hot-melt coating technology. I. Influence of Compritol 888 ATO and granule size on theophylline release. Drug Dev Ind Pharm. 2000;26(2):167-76.

149. Faham A, Prinderre P, Piccerelle P, Farah N, Joachim J. Hot melt coating technology: influence of Compritol 888 ATO and granule size on clonazepam release. Pharmazie. 2000;55(6):444-8.

150. Farah N, Barthelemy P, Joachim J. Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a, matrix. US6194005 B1, 2001.

151. Griffin EN, Niebergall PJ. Release kinetics of a controlled-release multiparticulate dosage form prepared using a hot-melt fluid bed coating method. Pharm Dev Technol. 1999;4(1):117-24.

152. Hamdani J, Goole J, Moës AJ, Amighi K. In vivo and in vitro evaluation of floating riboflavin pellets developed using the melt pelletization process. Int J Pharm. 2006;323(1-2):86-92.

153. Hamdani J, Moës AJ, Amighi K. Development and in vitro evaluation of a novel floating multiple unit dosage form obtained by melt pelletization. Int J Pharm. 2006;322(1-2):96-103.

154. Jannin V, Berard V, Andres C. Modification of the drug release of ibuprofen by hot-melt coating with mixes of Compritol™ 888 ATO and non-ionic surfactants. AAPS. 2005;7(81):Article -0833.

155. Kavitha K, Deore RK, Tamizhmani TG. Preparation and evaluation of sustained release matrix tablets of tramadol hydrochloride using glyceryl palmitostearate. Trop J Pharm Res. 2010;9(3):275-81.

156. Knezevic Z, Gosak D, Hraste M, Rausl D, Khan MZI. Application of hot-melt coating process for designing a lipid based controlled release drug delivery system for highly aqueous soluble drugs. Chem Pharm Bull. 2009;57(4):464-71.

157. Li FQ, Hu JH, Deng JX, Su H, Xu S, Liu YJ. In vivo controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int J Pharm. 2006;324(2):152-7.

158. Molke M, Iqbal M, Rao KS. Formulation and evaluation of verapamil HCl gastroretentive floating tablet from matrices prepared using Compritol ATO 888. Res J Pharm Biol Chem Sci. 2010;1(3):422-30.

159. Obaidat AA, Obaidat RM. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm. 2001;52(2):231-5.

160. Parakh PV, Oh CK, Ritschel WA. Sustained release from Precirol® (glycerol palmito-stearate) matrix. Effect of mannitol and hydroxypropyl methylcellulose on the release of theophylline. Drug Dev Ind Pharm. 1986;12(8-9):1309-27.

161. Pfytte P, Faire V, Mancini L, Guerin C, Daste G, Illison C et al. Controlled release of a highly hydrophilic API from lipid microspheres obtained by prilling: Analysis of drug and water diffusion processes with X-ray-based methods. J Control Release. 2012;158(3):393-402.

162. Zhang YE, Schwartz JB. Melt granulation and heat treatment for wax matrix-controlled drug release. Drug Dev Ind Pharm. 2009;35(2):131-8.

163. Windbergs M, Strachan CJ. Kleinebudde P. Understanding the solid-state behaviour of triglyceride solid lipid extrudates and its influence on dissolution. Eur J Pharm Biopharm. 2009;71(1):80-7.

164. Windbergs M, Strachan CJ, Kleinebudde P. Investigating the principles of recrystallization from glyceride melts. AAPS PharmSciTech. 2009;10(4):1224-33.

165. Windbergs M, Strachan CJ, Kleinebudde P. Tailor-made dissolution profiles by extruded matrices based on lipid polyethylene glycol mixtures. J Control Release. 2009;137(3):211-6.

166. Becker K, Haack D, Salar-Bezhadi S, Zimmer A. Oral pharmaceutical composition comprising taste-masked N-acetylcyesteine. EP1316383.3; 2013.

167. Haupt M, Thommes M, Heidenreich A, Breitkreuz J. Lipo-based intraveasal drug delivery systems with controlled release of trosipom chloride for the urinary bladder. J Control Release. 2013;170(2):161-6.

168. Mayama H. Blooming theory of tristearin. Soft Matter. 2009;5(4):836-9.

169. Szuts A, Láng P, Ambrus R, Kiss L, Deli MA, Szabó-Révész P. The applicability of sucrose stearate in hot-melt technology. Ph.D. Thesis; University of Szeged, Szeged, 2009.

170. Szuts A, Láng P, Szuts A, Ambrus R, Szabóné RP. The preparation of orally disintegrating tablets using the melt pelletization method. Int J Pharm Investig. 2013;3(3):151-6.

171. Szuts A, Láng P, Szuts A, Ambrus R, Szabóné RP. The applicability of sucrose laurate in hot-melt technology. Int J PharmTech Res. 2009;1(4):1167-72.

172. Akiyama Y, Yoshioka M, Hori H, Hirai S, Kitamori N, Toguchi H. pH-independent controlled-release microspheres using polyglycerol esters of fatty-acids. J Pharm Sci. 1994;83(11):1600-7.

173. Abdelgany G, Prinderre P, Eouani C, Joachim J, Reynier JP, Piccerelle P. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. Int J Pharm. 2004;278(2):295-302.

174. Sakarkar DM, Dorle AK, Mahajan NM, Sudke SG. Design of sustained release pellets of ferrous fumarate using cow ghee as hot-melt coating agent. Int J Pharm Investig. 2013;3(3):151-6.

175. Sakarkar DM, Jaiswal SB, Dorle AK, Deshmukh VN. Application of cow ghee as hot melt coating agent in the design of sustained release pellets. Int J PharmTech Res. 2009;1(4):1167-72.

176. Sax G, Feil F, Schulze S, Jung C, Brauchle C, Winter G. Release pathways of interferon alpha 2a molecules from lipid twin screw extrudates revealed by single molecule fluorescence microscopy. J Control Release. 2012;162(2):295-302.

177. Becker K, Haack D, Salar-Bezhadi S, Zimmer A. Oral pharmaceutical composition comprising taste-masked N-acetylcyesteine. EP1316383.3; 2013.
Lipid-based Solid Oral Formulations

175. Malkin T. The polymorphism of glycerides. Prog Chem Fats Other Lipids. 1954;2:1–50.

176. Chapman D. The polymorphism of glycerides. Chem Rev. 1962;62(5):433–56.

177. Sato K. Crystallization behaviour of fats and lipids—a review. Chem Eng Sci. 2001;56(7):2255–65.

178. Ghota BS, Dyal SD, Narine SS. Lipid shortenings: a review. Food Res Int. 2002;35(10):1015–48.

179. Himawan C, Starov VM, Stapley AGF. Thermodynamic and kinetic aspects of fat crystallization. Adv Colloid Interface Sci. 2006;122(1-3):3–33.

180. Fang W, Mayama H, Tsujii K. Spontaneous formation of fractal structures on triglyceride surfaces with reference to their super water-repellent properties. J Phys Chem B. 2007;111(3):564–71.

181. Hong BY, Li D, Lei QF, Xu L, Fang WJ, Mayama H. Kinetics on formation of super water repellent surfaces from phase transformation in binary mixtures of trimyristin and tripalmitin. Colloids Surf A. 2012;388(1):130–6.

182. Witzel R, Mullertz A, Kanikanti VR, Hamann HJ, Kleinedudde P. Dissolution of solid lipid extrudates in biorelevant media. Int J Pharm. 2012;422(1-2):116–24.

183. Khan N, Craig DQM. Role of blooming in determining the storage stability of lipid-based dosage forms. J Pharm Sci. 2004;93(12):2962–71.

184. Roussin P, Duddu S. Semi-solid matrix of polyglycolized glycerides. Drug Dev Ind Pharm. 2003;29(5):489–96.

185. Amrutkar PP, Patil SB, Todarwal AN, Wagh MA, Kothawade PD, Filipovic-Grcic J. Preparation and evaluation of a melt pelletised paracetamol/stearic acid sustained release delivery system. Spectrosc Int J. 2004;18(2):375–81.

186. Griffin WC. Calculation of HLB values of non-ionic surfactants. J Soc Cosmet Chem. 1954;5(4):249–56.

187. Grassi M, Voinovich D, Grabmar I, Franceschini E, Perissuti B, Filipovic-Gricic J. Preparation and in vitro/in vivo characterisation of a melt pelleted paracetamol/stearic acid sustained release delivery system. Spectrosc Int J. 2004;18(2):375–86.

188. Grassi M, Voinovich D, Moregnini M, Franceschini E, Perissuti B, Filipovic-Gricic J. Preparation and dissolution of a melt pelleted paracetamol/stearic acid sustained release delivery system. J Control Release. 2003;88(3):381–91.

189. Bakala N’Goma JC, Amara S, Dridi K, Janvin F, Carriere F. Understanding the lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems. Ther Deliv. 2012;3(1):105–24.

190. Ljusberg-Wahren H, Nielsen FS, Brogard M, Troedsson E, Bakala N. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur J Pharm Sci. 2001;14(2):115–22.

191. Christensen JO, Schultz K, Møllgaard B, Kristensen HG, Mullertz A. Enzymatic characterization of lipid-based drug delivery systems. Int J Pharm. 2005;298(2):328–32.

192. Zhangenber NH, Mullertz A, Kristensen HG, Hofgaard L. A dynamic in vitro lipolysis model I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci. 2001;14(2):1–11.

193. Christensen JO, Stroppa VLZ, de Oliveira GM, et al. Crystallization methodologies for taste masked oral dosage forms. J Control Release. 2014;173:32–42.

194. Yoajima T, Itai S, Takeuchi H, Kawashima Y. Optimum heat treatment conditions for masking the bitterness of the clarithromycin wax matrix. Chem Pharm Bull. 2003;51(11):1223–6.

195. Voertz K, Tissen C, Kleinedudde P, Breitkreutz J. Development of a taste-masked generic ibuprofen suspension: top-down approach guided by electronic tongue measurements. J Pharm Sci. 2011;100(10):4460–70.

196. Montague E, Langenheim M, Salerno C, Buontempo F, Bregni C, Carlucci A. Pharmaceutical optimization of lipid-based dosage forms for the improvement of taste-masking, chemical stability and solubilizing capacity of phenobarbital. Drug Dev Ind Pharm. 2014;40(6):785–92.

197. Sato K, Ueno S. Physical properties of fats in food. In: Rajab K, editor. Fats in food technology. Chichester: Wiley; 2014. p. 1–38.

198. Marangoni AG, Wesdorp LH. Structure and properties of fat crystal networks. Boca Raton: CRC Press Taylor & Francis Group. 2013.

199. Schulze S, Winter G. Lipid extrudates as novel sustained release systems for pharmaceutical proteins. J Control Release. 2009;134(3):177–85.

200. Windbergs M, Gueres S, Strachan CJ, Kleinedudde P. Two-step solid lipid extrusion as a process to modify dissolution behavior. AAPS PharmSciTech. 2010;11(1):2–8.

201. Keitz C, Kleinedudde P. Spheroidization of solid lipid extrudates. Powder Technol. 2009;192(2):238–44.

202. Omara M. Studying the release of diclofenac sodium from glycerides. Int J Pharm Pharm Sci. 2013;5(4):119–27.

203. Smith KW, Bhagavan T, Talbot G, Malsen KF. Crystallization of fats: influence of minor components and additives. J Am Oil Chem Soc. 2011;88(8):1085–101.

204. Ribéreau APB, Masuchi MH, Miyasaka EK, Domingues MAF, Stroppa VLZ, de Oliveira GM, et al. Crystallization modifiers in lipid systems. J Food Technol Pharmacol. 2014. doi:10.1007/s13197-014-1587-0.

205. Lopes DG, Becker K, Faulhammer E, Haack D, Lochmann D, Kihast JG, et al. Advanced structuring of lipids for controlled drug release; polymorphic crystallizations and curing effects. Atlanta: 14 AlChE Annual Meeting; 2014.

206. Xia D, Cui F, Gan Y, Mu H, Yang M. Design of lipid matrix formulations for delayed foodstuff release: effect of polymorphism of glycerol monoesterate on drug incorporation and release. J Pharm Sci. 2014;103(2):697–705.

207. Rudin T, Zehner M, Marquardt M, Marmeset N, Drexler H, et al. Polymorphism and growth behavior of low-trans fat blends formulated with and without emulsifiers. J Am Oil Chem Soc. 2006;83(6):489–96.

208. Herrera ML, Marquez Rocha FJ. Effects of sucrose ester on the kinetics of polymorphic transition in hydrogenated sunflower oil. J Am Oil Chem Soc. 1996;73(3):321–6.
217. Oh J-H, McCurdy AR, Clark S, Swanson BG. Stabilizing polymorphic transitions of tristearin using diacylglycerols and sucrose esters. J Am Oil Chem Soc. 2005;82(1):13–9.

218. Aronhime JS, Sarig S, Garti N. Dynamic control of polymorphic transformation in triglycerides by surfactants: the button syndrome. J Am Oil Chem Soc. 1988;65(7):1144–50.

219. Garti N, Wellner E, Sarig S. Crystal structure modifications of tristearin by emulsifiers. J Am Oil Chem Soc. 1982;59(4):181–5.

220. Aronhime JS, Sarig S, Garti N. Mechanistic considerations of polymorphic transformations of tristearin in the presence of emulsifiers. J Am Oil Chem Soc. 1987;64(4):529–33.

221. Gowan GW, Bruce RD. Aliphatic esters as a solventless coating for pharmaceuticals. CA 2082137; 1992.

222. Yoshioka M, Horibe H, Kashihara T. Granulated preparations and SFT probes. Drug Dev Ind Pharm. 2004;30(8):817–29.

223. Vial-Bernasoni AC, Buri P, Doelker E, Byscass E, Duchaux G, Aiache JM. In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolised glycerides. Pharm Acta Helv. 1995;70(4):307–13.

224. Thomas A, Müller SS, Frey H. Beyond poly(ethylene glycol): linear polyglycerol as a multifunctional polyether for biomedical and pharmaceutical applications. Biomacromolecules. 2014;15(6):1935–54.

225. Sutananta W, Craig DQM, Newton JM. An investigation into the properties of pharmaceutical glyceride bases. Int J Pharm. 1994;110(1):73–91.

226. Piette P, Fairey V, Brubach JB, Duste G, Ollivon M, Lesieur S. Polymorphism of glycerol behenates: from the individual compounds to the pharmaceutical excipient. Chin Phys Lipids. 2014;183:191–203.

227. Long C, Zhang L, Qian Y. Preparation and crystal modification of ibuprofen-loaded solid lipid microcapsules. Chin J Chem Eng. 2006;14(4):518–25.

228. Patel JK, Patel NV, Shah SH. In vitro release controlled colon targeted mesalamine from Compritol ATO 888 based matrix tablets using factorial design. Res Pharm Sci. 2009;4(2):63–75.

229. Bhoo PS. Quality by Design (QbD) for holistic pharma excellence and regulatory compliance. Pharm Times. 2014;46(8):26–33.

230. Guidance for industry—Q8(R2) pharmaceutical development. Food and Drug Administration; 2009: p. 1-25.

231. Guidance for industry—Q3A impurities in new drug substances. Food and Drug Administration; 2008: p. 1–14.

232. World Health Organization. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. World Health Organ Tech Rep Ser. 2009;953:387–130.

233. Breitkreutz J, Matlainen J. Lipid pellets with enhanced taste-masking. US20110262549 A1; 2011.

234. El-Refaie W, El-Massik M, Abdallah O, Khalfallah N. Formulation and evaluation of taste-masked paracetamol-lipid tablets and chewable tablets. J Pharm Investig. 2014;44(6):431–42.

235. Vaassen J, Bartscher K, Breitkreutz J. Taste masked lipid pellets with enhanced release of hydrophobic active ingredient. Int J Pharm. 2012;429(1-2):99–103.

236. Lakkis JM. Encapsulation and controlled release in hackery applications. In: Lakkis JM, editor. Encapsulation and controlled release technologies in food systems. Ames: Blackwell Publishing Inc.; 2007. p. 113–134.

237. Mehury E, Vervaeck G, Remon JP. Hot-melt extruded ethylcellulose cylinders containing a HPMC-Gelucire® core for sustained drug delivery. J Control Release. 2004;94(2-3):273–80.

238. Shiino K, Iwao Y, Miyagishima A, Itai S. Optimization of a novel wax matrix system using aminooxalkyl methacrylate copolymer E and ethylcellulose to suppress the bitter taste of acetaminophen. Int J Pharm. 2010;395(1-2):71–7.

239. Dordoomoo SK, Ford JL, Rubinstein MH. Solidification studies of polyethylene glycols, gelucire 44/14 or their dispersions with triamterene or temazepam. J Pharm Pharmacol. 1996;48(8):782–9.

240. Bodmeier R, Paeratakul O, Chen H, Zhang W. Formation of sustained release wax matrices within hard gelatin capsules in a fluidized bed. Drug Dev Ind Pharm. 1999;16(9):1503–19.

241. Galal S, El Massik MA, Abdallah OY, Daabis NA. Study of in-vitro release characteristics of carboxamipazine extended release semisolid matrix filled capsules based on gelucires. Drug Dev Ind Pharm. 2002;24(3):119–24.

242. Bhoop BS. Quality by Design (QbD) for holistic pharma excellence and regulatory compliance. Pharm Times. 2014;46(8):26–33.

243. Dennis AB, Farr SJ, Kelloway IW, Taylor G, Davidson R. In vivo evaluation of rapid release and sustained release gelurice capsule formulations. Int J Pharm. 1990;65(1-2):83–100.

244. Keen JM, McGinity JW, Williams IIIO. Enhancing bioavailability through thermal processing. Int J Pharm. 2013;450(1-2):183–96.

245. Quinten T, De Beer T, Vervaeck C, Remon JP. Evaluation of injection moulding as a pharmaceutical technology to produce matrix tablets. Eur J Pharm Biopharm. 2009;71(1):45–54.

246. Cheboyina S, Wyandt CM. Wax-based sustained release matrix pellets prepared by a novel freeze pelletisation technique - I. Formulation and process variables affecting pellet characteristics. Int J Pharm. 2008;359(1-2):158–66.

247. Shulda D, Chakraborty S, Singh S, Mishra B. Pastillation: a novel technology for development of oral lipid based multiparticulate controlled release formulation. Powder Technol. 2011;209(1-3):65–72.

248. Kato Y, Sunada H, Yonezawa Y, Ishino R. Sustained-release mechanisms of wax matrix system for controlled-release. Chem Pharm Bull. 1994;42(8):1646–50.

249. Srivastava S, Mishra G. Fluid bed technology : overview and parameters for process selection. Int J Pharm Sci Drug Res. 2010;2(4):236–46.

250. Jumain V, Cuppok Y. Hot-melt coating with lipid excipients. Int J Pharm. 2013;457(2):480–7.

251. Barbosa-Canovas GV, Ortega-Rivas E, Pablo J, Yan H. Food powders: physical properties, processing, and functionality. New York: Kluwer Academic/Plenum Publishers; 2005.

252. Walker G, Bell SEJ, Vann M, Jones DS, Andrews G. Fluidised bed characterisation using Raman spectroscopy: applications to pharmaceutical processing. Chem Eng Sci. 2007;62(14):3832–8.

253. Bogomolov A, Engler M, Melichar M, Wigmore A. In-line analysis of a fluid bed pellet coating process using a combination of near infrared and Raman spectroscopy. J Chemom. 2010;24(7-8):544–7.

254. Lee MJ, Seo DY, Lee HE, Wang IC, Jeong MY, et al. In line NIR quantification of film thickness on pharmaceutical pellets during a fluid bed coating process. Int J Pharm. 2011;403(1-2):66–72.

255. Kukuc S, Hudovnik G, Dreu R, Vrecre F. Study of granule growth kinetics during in situ fluid bed melt granulation using in-line FBRM and SFT probes. Drug Dev Ind Pharm. 2014;40(7):952–9.
